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1 Summary
Prion diseases are transmissible neurodegenerative disorders, fatally affecting humans and an-
imals. The prion protein (PrP) is indispensable for prion disease, as mice devoid of PrP do not
succumb to disease. Prion disease relies on the seeded nucleation of the “scrapie” conformer
PrPSc onto the cellular prion protein PrPC. The molecular mechanisms underlying the con-
formational alterations from PrPC to PrPSc are still unknown. Chaperones are involved in the
correct folding of proteins and can specifically unfold misfolded proteins, actively disaggreggate
aggregated proteins, and convert them into harmless native proteins or fragmented peptides.
The role of chaperones as potent suppressors of neurodegeneration is well-established. How-
ever, no comprehensive study including all mammalian chaperones has been achieved in prion
research. I hence propose to shed light on the factors involved in the correct folding of PrPC by
identifying chaperones, that are involved in PrPC biosynthesis by siRNA mediated screens. In
addition I plan to identify chaperones involved in the misfolding from PrPC to PrPSc or potential
un-folding or disaggregation of PrPSc. This approach is plenary and unbiased because siRNAs
targeting the entire mammalian repertoire of chaperones, e.g. the “chaperome”, are used in
the screens. Because chaperones collaborate with one or two co-chaperones to compensate
functional failure, I plan to simultaneously knock down two or three chaperones, after having
evaluated single knockdown screens.
My first aim is to establish siRNA screens targeting chaperone genes in murine cells with PrPC
and PrPSc levels as readout. I completed two murine PrPC single knock down screens with two
different siRNA libraries targeting druggable and non-druggable chaperones in the neuronal
CAD5 cell line. In total I screened 239 chaperones in ten 384-well plates. The screens passed
quality control. Viability results were used to define thresholds for extreme low or high cell
viability and implemented in the analysis of the PrP levels to select chaperones altering the
PrP metabolism rather than cell viability. Of total 936 siRNAs, 26 siRNAs led to upregulation
of PrPC, whereas 82 siRNAs led to substantial downregulation of PrPC levels. My screens
validated the role of Hspa5 and Hsf1 in prion protein metabolism and furthermore discovered
21 novel chaperones involved in PrP metabolism. The majority of the genes leading to reduc-
tion of PrPC were involved in protein processing in the endoplasmatic reticulum or were part of
the 26S proteasome. I started to establish the murine PrPSc screen with a FRET assay and
acute infection of CAD5 cells with RML6 prions. Because FRET was not sensitive enough to
detect differences between uninfected and RML6 infected CAD5, I established PrPSc-ELISA.
Acute infection of CAD5 and CAD5 Prnp-/-cells with RML6 resulted in high amounts of resid-
ual inoculum in CAD5 Prnp-/- cells, masking potential prion replication in CAD5 wild type cells.
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By chronically infecting CAD5 cells, residual inoculum was completely removed in four con-
secutive splitting steps. PrPSc-ELISA with chronically infected scCAD5 resulted in very low
ELISA signal. In order to get a higher signal, I had generated hyCAD5 cells overexpressing
PrP. I chronically infected hyCAD5 cells with RML6 prions (scHyCAD) and transfected them
with control siRNAs. PrPSc-ELISA showed good strictly standardized mean difference (SSMD)
values for manually performed forward transfection, but insufficient knockdown efficiency and
high inter-well variability with robotic reverse transfection. Therefore, I established the PrPSc
screen on the robotic platform for forward transfection with chronically infected hyCAD5 cells.
The test screen with control siRNAs resulted in good SSMD values. When I performed the
PrPSc screen, the viability quality control showed six siRNAs reducing the viability of the cells
significantly.
My second aim is to generate a murinized human cell line susceptible to murine prions to
perform a human PrPSc screen with murine prions without elevated biosafety risk that would
arise when working with human prions. Subsequently I plan to establish an siRNA screen
targeting chaperone genes in human murinized cells with PrPC and PrPSc levels as readout.
I generated PRNP knock-out mutants in the human SH-SY5Y cell line by means of CRISPR-
Cas9 and generated murinized SH-SY5Y cells by stable transfection of a PRNP knockout clone
with murine Prnp and subsequent clonal isolation by limited dilution. To assess strain specific
susceptibility to murine prions, I acutely infected a pool of seven murinized clones (mSY5Y),
as well as single clone #M4 with eight different prion strains and according non-infectious brain
homogenate. Western blots showed Proteinase K resistant PrPSc bands with the prion strains
79A, mNS and ME7. When I chronically infected mSY5Y and single clone #M4 with these three
strains, no PrPSc band was visible. The screen would only have been feasible with chronically
infected cells, because residual inoculum in SH-SY5Y cells acutely infected with 79A, mNS
and ME7 prions masked potential PrPSc replication. In an alternative approach, I generated
a human glioblastoma cell line U-251MG overexpressing murine PrP. I acutely infected mixed
clones of U-251MG overexpressing murine PrP and un-transfected cells as negative control
with murine RML6 prions. Western blots showed that U-251MG did neither replicate RML6
prions, nor human prions.
My third aim is to compare and validate hits from murine and human screens. I extracted
the same genes that were screened in the two murine PrPC screens from a human genome
wide PrPC screen and performed a side-by-side comparison. The comparison showed six
genes, that led to downregulation of PrP in murine and human PrPC screens. I established hit
validation by Western blotting and qRT-PCR on the LabCyte acoustic dispensing robot for 384-
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well plate format. To test alternative murine cell lines for hit validation, I successfully acutely
and chronically infected N2A PK1 cells with RML6 prions. The murine myoblastoma cell line
CH3H/10T1/2 of which I had generated Prnp-/- clones by CRISPR-Cas9 seemed not to be
susceptible to RML6 and thus not suitable for hit validation.
Screening the entire chaperome allowed me to detect unexpected hits involved in the metabolism
of PrP. A detailed understanding of the molecular basis of chaperone interactions with PrP,
could contribute to the general understanding of other protein misfolding diseases such as
Alzheimer’s, Parkinson’s or ALS.
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2 Zusammenfassung
Prionenerkrankungen sind u¨bertragbare, neurodegenerative Krankheiten, die im Menschen
und in Tieren vorkommen. Da Ma¨use ohne das Prionenprotein (PrP) gegen die Krankheit
resistent sind, geht man davon aus, dass das Prionenprotein fu¨r die Krankheit unabding-
bar ist. Das falsch gefaltete Prionenprotein (PrPSc) u¨bertra¨gt seine Konformation auf das
richtig gefaltete zellula¨re Prionenprotein (PrPC) mittels Nukleation, die durch Zugabe von PrPSc
beschleunigt wird. Die molekularen Mechanismen, welche an der Konformationsa¨nderung
vom zellula¨ren PrPC zum falsch gefaltetem PrPSc beteiligt sind, sind noch nicht bekannt.
Chaperone sind in die korrekten Faltung von Proteinen involviert und ko¨nnen gezielt falsch
gefaltete Proteine entfalten. Zudem zerteilen sie aggregierte Proteine und wandeln sie in
ungefa¨hrliche, korrekt gefaltete Proteine oder fragmentierte Peptide um. Chaperone wirken
protektiv gegen neurodegenerative Erkrankungen. In der Prionenforschung gibt es bis jetzt
noch keine umfassenden Studien, die sa¨mtliche Chaperone, die in Sa¨ugetieren vorkommen,
untersucht haben. Deshalb habe ich mir zum Ziel gesetzt, Moleku¨le ausfindig zu machen, die
an der korrekten Faltung von PrPC sowie an der Fehlfaltung von PrPC zu PrPSc beteiligt sind.
Zudem wollte ich Moleku¨le identifizieren, welche PrPSc potentiell wieder in die richtige Konfor-
mation zuru¨ckfalten oder Aggregate auflo¨sen ko¨nnen. Mittels siRNA screens wollte ich Chap-
erone identifizieren, die an der Biosynthese von PrPC und der Replikation von PrPSc beteiligt
sind. Dieser Ansatz ist vollsta¨ndig und unvoreingenommen, da mittels siRNAs die Gesamtheit
der Chaperone untersucht wird, die in Sa¨ugetieren vorkommen. Chaperone arbeiten mit Co-
Chaperonen zusammen, welche bei Ausfall eines Chaperones dessen Funktion u¨bernehmen
ko¨nnen. Deshalb beabsichtigte ich zwei oder drei Chaperone gleichzeitig zu untersuchen.
Mein erstes Ziel bestand darin, einen siRNA screen mit Mauszellen zu etablieren, mit dem
PrPC- und PrPSc-Werte gemessen werden ko¨nnen. Mittels zweier verschiedener Sammlun-
gen von siRNAs, welche die Expression von Chaperonen reduzieren, habe ich zwei Screens
mit neuronalen Mauszellen durchgefu¨hrt. Insgesamt habe ich 293 Chaperone in zehn 384-
Kavita¨tenplatten untersucht. Die Screens haben die Qualita¨tskontrollen bestanden. Zusa¨tzlich
zu den PrP-Werten wurde die Vitalita¨t der Zellen gemessen und in die Analyse der PrP-
Werte implementiert. Zellen mit enorm hoher oder tiefer Vitalita¨t wurden ausgeschlossen,
um Information u¨ber den Metabolismus des Prionenproteins und nicht u¨ber die Vitalita¨t der
Zellen zu erhalten. Von total 963 siRNAs erho¨hten 26 siRNAs die Werte von PrPC. 82 siR-
NAs fu¨hrten zu tieferen PrPC Werten. Meine Screens besta¨tigten die Beteiligung der Gene
Hspa5 und Hsf1 im Metabolismus von PrP. Zudem entdeckte ich 21 neue Chaperone, die
am Metabolismus von PrP beteiligt sind. Die Mehrheit dieser Gene war in die Prozessierung
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von Proteinen im Endoplasmatischen Retikulum involviert, oder war Teil des 26S Proteasoms.
Ich setzte den PrPSc-Mausscreen mit PrPSc als Readout mit der FRET Methode sowie mit
akuter Infektion von neuronalen CAD5 Zellen mit RML6 Prionen auf. Da die FRET Methode
nicht ausreichend empfindlich war, um infizierte von uninfizierten Zellen zu unterscheiden,
etablierte ich die PrPSc-ELISA Methode. Akute Infektion von CAD5 Zellen und CAD5 Prnp
knockout Zellen mit RML6 Prionen zeigte restliches RML6 in den CAD5 Prnp knockout Zellen.
Deshalb infizierte ich die Zellen chronisch anstatt akut. Durch vierfaches Passagieren der
Zellen wurde das restliche RML6 von den Zellen entfernt. Das Signal mit chronisch infizierten
CAD5 Zellen, gemessen mit der PrPSc-ELISA Methode, war sehr schwach. Deshalb gener-
ierte ich hyCAD5 Zellen, die PrP u¨berexprimieren. Ich infizierte die hyCAD5 Zellen chronisch
mit RML6 Prionen (scHyCAD) und transfizierte sie mit Kontroll-siRNAs. Die SSMD Resultate
des PrPSc-ELISAs mit ha¨ndischer Vorwa¨rts-Transfektion waren gut. Ru¨ckwa¨rts-Transfektion
mit dem Roboter reduzierte die Effizienz der Transfektion und erho¨hte die Variabilita¨t zwis-
chen einzelnen Kavita¨ten. Deshalb setzte ich den PrPSc screen auf den Roboteranlagen fu¨r
Vorwa¨rts-Transfektion auf. Der Testscreen mit Kontroll-siRNAs zeigte gute SSMD Werte. Als
ich den PrPSc Screen durchfu¨hrte, zeigte die Qualita¨tskontrolle der Vitalita¨t der Zellen sechs
siRNAs, die die Vitalita¨t der Zellen stark reduzierte.
Mein zweites Ziel war es, eine murinisierte menschliche Zelllinie zu generieren, die auf murine
Prionen anfa¨llig ist. Auf diese Weise konnte ich einen humanen Screen ohne das Risiko
durchfu¨hren, das entsteht, wenn man Experimente mit humanen Prionen durchfu¨hrt. Daru¨ber
hinaus beabsichtigte ich einen siRNA screen mit menschlichen murinisierten Zellen durchzufu¨hren
und humane Chaperone zu screenen. Ich generierte PRNP knockout Mutanten der huma-
nen Zelllinie SH-SY5Y mittels CRISPR-Cas9. Ich transfizierte einen PRNP knockout Klon
mit murinem Prnp und isolierte anschliessend murinisierte Klone. Um die Anfa¨lligkeit der
murinisierten Zellen auf murine Prionen zu testen, infizierte ich eine Mischung aus sieben
murinisierten Klonen sowie den einzelnen Klon #M4 mit acht verschiedenen Prionensta¨mmen.
Western Blots zeigten Proteinase K resistente PrPSc Banden nach Infektion mit den Prio-
nensta¨mmen 79A, mNS und ME7. Als ich mSY5Y und den Klon #M4 chronisch mit diesen
drei Prionensta¨mmen und RML6 infizierte, waren keine PrPSc Banden mehr sichtbar. Ein
PrPSc Screen wa¨re nur mit chronisch infizierten Zellen realisierbar gewesen. Reste von Inoku-
lum, die bei akuter Infektion entstehen, wu¨rden potentielle Prionenreplikation u¨berdecken. Mit
einem anderen Ansatz generierte ich die menschliche Glioblastoma Zelllinie tU-251-MG, die
murines PrP u¨berexprimiert. Ich infizierte PrP u¨berexprimierende Zellen sowie untransfizierte
Zellen akut mit RML6 Prionen. Western Blots zeigten, dass tU-251-MG weder humane noch
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murine RML6 Prionen repliziert.
Mein drittes Ziel bestand aus dem Vergleich und der Validierung von Hits aus den murinen
und humanen Screens. Ich extrahierte dieselben Gene, die ich auch in den zwei murinen
Screens untersucht hatte, aus einem humanen genomweiten Screen. Anschliessend verglich
ich die Resultate der murinen Screens mit dem humanen Screen. Der Vergleich resultierte in
sechs Genen, die PrP in den murinen sowie im humanen Screen reduzierten. Ich etablierte
die Validation von Hits mittels Western Blots und qRT-PCR auf der LabCyte Roboteranlage
fu¨r 384-Kavita¨tenplatten. Um alternative murine Zelllinien zu finden, infizierte ich N2A PK1
Zellen erfolgreich akut und chronisch mit RML6 Prionen. Die murine Myoblastoma Zelllinie
CH3H/10T1/2, von welcher ich mittels CRISPR-Cas9 knockout Klone generiert hatte, schien
nicht anfa¨llig auf RML6 Prionen zu sein und war deshalb nicht geeignet fu¨r die Validierung von
Hits.
Durch das Screenen des ganzen Chaperomes habe ich unerwartete Hits entdeckt, die am
Metabolismus von PrP beteiligt sind. Ein exaktes Versta¨ndnis der molekularen Grundlage von
Interaktionen zwischen Chaperonen mit PrP ko¨nnte zum allgemeinen Versta¨ndnis von anderen
Proteinfehlfaltungserkrankungen wie Alzheimer, Parkinson oder ALS beitragen.
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3 Abbreviations
+/- In the presence and in the absence of
aa Amino acid
A  Amyloid  
AD Alzheimer’s disease
ALS Amyotrophic lateral sclerosis
BH Brain homogenate
BSA Bovine serum albumin
BSE Bovine spongiform encephalopathy
CAD5 CAD-2A2D5 cell line responsive to RML, 22L, 79A, ME7, 301C prion strains
CJD Creutzfeldt-Jakob’s disease (including sCJD, vCJD, iCJD, gCJD)
CNS Central nervous system
CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
CWD Chronic wasting disease
DNA Deoxyribonucleic acid
dpe Days post-exposure
dpi Days post-infection
DPR Dipeptide repeat proteins
EDTA Ethylenediaminetetraacetic acid
eGFP Enhanced GFP
ELISA Enzyme-linked immunosorbent assay
ER Endoplasmic reticulum
FACS Fluorescence-activated cell sorting
FBS Fetal bovine serum
fCJD familial Creutzfeldt-Jakob’s disease
FFI Familial fatal insomnia
FTD Frontotemporal Dementia
gCJD genetic Creutzfeldt-Jakob’s disease
GFP Green fluorescent protein
GPI Glycosylphosphatidylinositol
gCJD Genetic Creutzfeldt-Jakob’s disease
GPCR G-protein coupled receptor
GSS Gerstmann-Stra¨ussler-Scheinker disease
HP FRET Homogeneous phase fluorescence resonance energy transfer
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HD Huntington’s disease
hPrPC Human cellular prion protein
HRP Horseradish peroxidase
iCJD iatrogenic Creutzfeldt-Jakob’s disease
IgG Immunoglobulin G
kDa kilo Dalton
KO Knockout
mRNA Messenger RNA
NBH Non-infectious brain homogenate
NMR Nuclear magnetic resonance
ORF Open reading frame
PCR Polymerase chain reaction
PD Parkinson’s disease
PK Proteinase K
PK-Western Western blot with samples digested with PK
POM 1 – 19 Set of 19 anto-PrP monoclonal antibodies
Prnp Prion protein gene (murine)
PRNP Prion protein gene (human)
PrP Prion protein
PrPC Cellular prion protein
PrPSc Scrapie prion protein
[ PSI+] Yeast protein, misfolded, self-propagating form of Sup35, analog to mam-
malian PrPSc
qRT-PCR quantitative Real Time PCR
recPrP Recombinant PrP (rhPrP23-231 + rmPrP23-230)
rhPrP23-231 Recombinant, full-length human PrP, aa 23-231
RML6 Passage 6 of the Rocky Mountain Laboratory strain mouse-adapted scrapie
prions
rmPrP23-230 Recombinant, full-length murine PrP, aa 23-230
RNA Ribonucleic acid
RNAi RNA interference
RISC RNA-induced silencing complex
sCJD sporadic Creutzfeldt-Jakob’s disease
SD Standard deviation
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
sgRNA single guide RNA
SKD Single knockdown
SRP signal recognition particle
SSMD Strictly standardized mean difference
Sup35 Yeast protein, important for translation termination, analog to mammalian PrPC
TRAM Translocating chain associating membrane protein
TRAP Translocon associated protein
TSE Transmissible spongiform encephalopthy
UPR Unfolded protein response
UPS Ubiquitin proteasome system
vCJD variant Creutzfeldt-Jakob’s disease
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4 Introduction
4.1 History of prions
Prion disease was first described 1732 in Merino sheep manifested by abnormal behavior
such as altered gait and intense itching that caused affected sheep to pathologically scrape
against fences (Figure 1). The disease was called Scrapie and classified as the first member
of transmissible spongiform encephalopathies (TSEs) (Zabel and Reid 2015). In 1920, a hu-
man neurological disorder of unknown etiology described by the neurologists Hans Gerhard
Creutzfeldt and Alfons Maria Jakob was termed Creutzfeldt-Jakob’s disease (CJD) (Creutzfeldt
1920, Jakob 1921, Kovacs, Trabattoni et al. 2002). Based on findings that viral nucleic acids
encode genetic information and were infectious, Sigurdsson hypothesized that the scrapie dis-
ease was caused by a “slow virus” in 1954 (Sigurdsson 1954). In the same year scientists
discovered the human neurological disorder Kuru in Papua New Guinea among the Fore tribe,
transmitted by practice of cannibalism, with similar symptoms as CJD and scrapie (Gajdusek
and Zigas 1959). Hadlow, Klatzo, Gajdusek and Zigas linked 1959 Kuru, scrapie and CJD
by showing they were distinct forms of the same neuropathy (Hadlow 1959, Klatzo, Gajdusek
et al. 1959). 1966 Alper discovered that the scrapie agent was resistant to high amounts
of UV radiation and therefore could not consist of nucleic acids (Alper 1967). Contradicting
the central dogma of biology, T. Alper, I.H. Pattison and J.S Griffith proposed that the scrapie
agent could be of protein origin. Patricia Merz detected scrapie associated fibrils in murine
CJD brain fractions in experimentally transmitted disease as well as in human cases of CJD
(Merz, Somerville et al. 1983). Stanley Prusiner delivered evidence for the “protein only”
hypothesis by inactivating the scrapie agent, that he had isolated from affected animals, by
methods that destroyed proteins. In 1982 Prusiner designated the term ’prion’, derived from
proteinaceous infectious particle, to describe the infectious scrapie agent (Bolton, Mckinley et
al. 1982, Prusiner, Bolton et al. 1982, Prusiner, Mckinley et al. 1983). Three years later Bruce
Chesebro and Richard Race found an mRNA transcript from the protease-resistant prion agent
isolated by Prusiner. Unexpectedly, they found this prion protein mRNA in both infected and
uninfected brain tissue (Chesebro, Race et al. 1985, Locht, Chesebro et al. 1986). The same
year Prusiner and Charles Weissman detected the host gene encoding the prion agent, and
the locus named Prnp was isolated by George Carlson and Prusiner (Oesch, Westaway et
al. 1985). Mice devoid of Prnp were resistant to scrapie, showing physiologically expressed
PrPC was necessary for prion infection (Bueler, Aguzzi et al. 1993). 1986 British pathologists
identified a scrapie like disease which previously had been known to occur only in sheep and
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Figure 1: Milestones in the history of prion research. Adapted from (Zabel et al. 2015).
goats within food animals. They named the disease bovine spongiform encephalopathy (BSE).
Detergent treated fibrils, extracted from BSE affected cattle shared morphological, chemical
and immunological properties with scrapie-associated fibrils found in all other members of the
disease group. The fibrils were transmissible from cattle brain to mice by intracerebral and
intraperitoneal inoculation. These results provided conclusive evidence that BSE was a new
member of TSEs (Bradley 1990). The principle of prion replication was confirmed in yeast.
Analogous to mammalian prions, yeast prions were shown to convert their normal cellular iso-
forms into misfolded isoforms (Glover, Kowal et al. 1997). The normal protein isoforms Ure2p
and Sup35 are indispensable to generate and maintain their prion forms [URE3] and [PSI+].
Both prion forms appear more frequently when Ure2p and Sup35 were overexpressed. Follow-
ing generations inherit both elements as non-Mendelian dominant traits (Cox 1994). Skeptics
dismissed the “protein only” hypothesis, because de novo prion generation experiments relied
on extraction of PrPC from living animals that might harbor a presumptive TSE virus. Spon-
taneous prion formation in vitro using a prion amplification technique and highly purified PrPC
from uninfected brain homogenate in combination with synthetic polyanions or using recom-
binant prion protein produced in bacteria, provided strong evidence that infectious prions lack
nucleic acids differing in the sequence from PrPC (Deleault, Geoghegan et al. 2005, Barria,
Mukherjee et al. 2009, Zhang, Zhang et al. 2013). The prion hypothesis therefore affirmed a
new paradigm of information storage and transfer in biological systems. Nowadays the “protein
only” hypothesis is widely accepted.
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4.2 Prion diseases
Prion diseases, also referred to as transmissible spongiform encephalopathies (TSEs), are
neurodegenerative disorders affecting humans and animals (Mabbott and MacPherson 2006).
TSEs are characterized by extensive neurodegeneration, manifested in neuronal loss, as-
trogliosis, microglial activation, spongiform change and aggregates of abnormally folded prion
protein (Soto and Satani 2011). Prion diseases are fatal neurodegenerative diseases, which
are currently incurable (Prusiner 1998). In animals, prion diseases include scrapie in sheep
and goats, chronic wasting disease (CWD) in moose deer and elk, and bovine spongiform
encephalopathy (BSE) in cattle (Brotherston, Renwick et al. 1968, Williams and Young 1980,
Bradley 1990). BSE was identified 1986 by British pathologists. In the following years BSE epi-
demically spread from England to numerous countries affecting over 280,000 animals (Aguzzi
and Calella 2009). BSE was transmitted by feeding cattle with meat and bone meal from an-
imals that were partially infected, as a nutritional supplement (Wilesmith, Ryan et al. 1992).
Since 1988, the use of dietary protein supplements derived from animals is forbidden for do-
mestic animals in the United Kingdom. A second delayed wave of BSE cases occurred in coun-
tries where the feeding of animal derived proteins was prohibited at later time points(Aguzzi
and Calella 2009). To date five prion diseases have been identified in humans: Creutzfeldt-
Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), Kuru, Gerstmann-Straa¨ussler-
Scheinker syndrome (GSS), and fatal familial insomnia (FFI) (Gibbs, Gajdusek et al. 1968,
Medori, Tritschler et al. 1992, Brown, Preece et al. 2000). Human prion diseases are classified
in iatrogenic, genetic or sporadic origin according to the transmitted, inherited or spontaneously
misfolded source of PrPSc (Hasier Eran˜a 2016). 85% of human prion diseases show sporadic
CJD (sCJD), 10 – 20% cases are familial (fCJD) and 1% of the cases are iatrogenically trans-
mitted (iCJD) (Aguzzi and Calella 2009). Susceptibilty of patients to sCJD, fCJD and iCJD
is influenced by an amino acid polymorphism at PrP codon 129, which can be homozygous
or heterozygous for Methionine or Valine (Owen, Poulter et al. 1990, Kitamoto and Tateishi
1994). Clinical signs overlap considerably between the different forms of CJD and manifest in
cognitive and motor dysfunction such as rapidly progressive dementia, myoclonus, visual or
cerebellar impairment, pyramidal or extrapyramidal signs, and akinetic mutism (Mabbott and
MacPherson 2006, Aguzzi, Baumann et al. 2008, Aguzzi and Calella 2009).
4.3 Structure of prion protein isoforms
Solution nuclear magnetic resonance (NMR) structural analyses and crystallographic studies
revealed 40% of human and murine PrPC consisted of ↵-helices and 3%  -sheets (Pan, Bald-
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win et al. 1993, Riek, Hornemann et al. 1996, Ohhashi, Kihara et al. 2005). While the amino-
proximal flexible tail is structurally less defined, the C-terminal globular domain is structured
into three ↵-helixes (amino acids 144–154, 175–193 and 200–219) and a small antiparallel
 -sheet (amino acids 128–131 and 161–164). Close to the small  -sheet, a disulfide bridge
between Cys-179 and Cys-214 connects helix 2 and helix 3 (Prusiner and Scott 1997, Riesner
2003, Aguzzi and Calella 2009, Zabel and Reid 2015) (Figure 2). Depending on the glycosy-
lation state at two Asparagine residues close to the C-terminus, mammalian PrPC measures
between 30 and 35 kDa (Riek, Hornemann et al. 1996). PrPC is characterized by ↵-helical
structure, proteinase K (PK) sensitivity, and solubility as a monomeric or dimeric molecule
(Riesner 2003).
Figure 2: NMR structure of a) human and b) murine PrPC. The ribbon diagram shows three ↵-helices (green) and
the two antiparallel  -sheets (blue). The connecting loops are displayed in green yellow. Reprinted from (Riesner
2003). License number 4375851429736.
Fourier-transform infrared measurements of PrPSc and CD spectroscopy show a conforma-
tional transition to  –sheets (40%) with only 30% ↵-helices. In addition to a  -sheet-rich
structure, the misfolded isoform PrPSc differs from PrPC in physicochemical properties. PrPSc
precipitates as an insoluble, detergent and protease-resistant aggregate of a core 27–30 kDa
protein fragment that retains infectivity. No high-resolution structure is available for PrPSc (Pan,
Baldwin et al. 1993, Safar, Roller et al. 1993, Riesner 2003).
4.4 Biosynthesis of PrPc
In all mammals and birds, the entire open reading frame (ORF) of the prion protein gene
is located within a single exon. The prion protein gene is found in the short arm of human
chromosome 20 and in a homologous region in mouse chromosome 2 (Sparkes, Simon et
al. 1986). The encoded prion protein is a widely expressed nonessential typical cell-surface
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glycoprotein (Chakrabarti, Ashok et al. 2009). PrP synthesis begins at the endoplasmatic
reticulum (ER) (Figure 3). As the N-terminal signal sequence is translated by the ribosome, it
Figure 3: Nascent PrP (black line) is synthesized by the ribosome. As the N-terminal signal sequence (blue)
emerges from the ribosome, it is recognized by the signal recognition particle (SRP, green) and interacts with the
Sec61 translocon (yellow). Accessory factors such as TRAM and TRAP (grey), contribute in opening of the Sec61
channel to initiate translocation. Forward transport into the ER lumen or prevention of translocation back to the
cytosol might be assisted by chaperones (grey). Fully translocated PrP attaches to the inner leaflet of the lipid
bilayer via a GPI anchor. Reprinted from (Chakrabarti, Ashok et al. 2009). License number 4375850573324.
is recognized by the signal recognition particle (SRP) and interacts with the Sec61 translocon
(Kim and Hegde 2002, Kim, Mitra et al. 2002). In combination with accessory factors such
as translocon associated protein (TRAP) and translocating chain associating membrane pro-
tein (TRAM), the Sec61 channel opens and translocation into the ER lumen is initiated (Fons,
Bogert et al. 2003). The entire ribosome–nascent chain complex is imported to the ER lu-
men. Chaperones might be involved in the forward transport into the lumen or in prevention
of translocation back to the cytosol (Chakrabarti, Ashok et al. 2009). Freshly translated PrP
undergoes several steps of posttranslational processing in the ER. PrP is glycosylated, a 22
amino acids long signal peptide is removed at the N-terminus, it is properly folded and a C-
terminal glycosylphosphatidyl inositol (GPI) anchor is added. Fully translocated PrP attaches
to the inner leaflet of the lipid bilayer via a GPI anchor (Stahl, Baldwin et al. 1993, Hebert
and Molinari 2007, Rapoport 2007). Properly folded PrP is trafficked through the Golgi (Fig-
ure 4). As PrP passes the Golgi apparatus, it receives various additional modifications to its
glycans and the GPI anchor. Most of mature PrP follows the common exocytic pathway to the
cell surface and the endocytic pathway to internal endosomal compartments. From there it is
either recycled to the cell surface or brought to lysosomes for degradation (Taylor and Hooper
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2006). PrP biosynthesis and trafficking to the cell surface takes around 30 min in a standard
cell, whereas degradation takes 6 to 12 hours (Caughey, Race et al. 1989, Borchelt, Scott et
al. 1990).
Figure 4: Overview of PrPC metabolism. 1) Nascent PrP (green line) is translocated into the ER lumen. 2) in
the ER PrP is posttranslationally processed and folded into its final conformation (green triangle). 3) Properly
folded PrP is trafficked through the Golgi to the cell surface 4). 5) Mature PrP follows the endocytic pathway to
internal endosomal compartments. From there it is either recycled to the cell surface 6) or brought to lysosomes
for degradation 7). Reprinted from (Chakrabarti, Ashok et al. 2009). License number 4375850573324.
4.5 Prion strains and species barrier
Prion diseases have two particularly intriguing features. Different prion strains and the species
barrier that limits the spread of infection between species (Liebman 2001). Prion strains are
defined as infectious extracts that, when inoculated to identical hosts, show distinct phenotypes
of prion disease. Based on clinical symptoms Pattison and Millson could show strain specific
transmission of PrPSc over 10 passages resulting in the “drowsy” and “scratching” syndromes
(Pattison IH 1960). Phenotypic traits can include as well specific locations of protein aggregate
accumulation. Prion strains propagate in the CNS, secondary lymphoid organs, spleen or
skeletal muscle (Glatzel, Abela et al. 2003, Aguzzi and Calella 2009). Another phenotypic trait
is the incubation period, defined as the time interval between infection and onset of the clinical
signs of the disease. The incubation period of different prion strains is determined after two or
three serial passages in different mouse lines. Incubation periods of prion strains are not only
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strain specific, but also species specific. (Beat Ho¨rnlimann 2007). Further phenotypic traits
include histopathological analyses, specific neuronal target areas and stability of biological
properties. Most of the strains are relatively stable over many passages. Based on their
stability, murine scrapie strains can be divided into three different classes. Class I strains
are completely stable, even when passaged in mouse lines of different genotypes or in other
species such as sheep or hamsters. ME7 strain is the prototype of a class I strain. Class II
strains are stable in the mouse genotype they originate from but modify their characteristics
during consecutive passages in other genotypes. As a typical class II strain 22A is stable
when passaged in VM mice, the mouse line used for its isolation. When 22A is passaged in
C57BL mice, the incubation periods and lesion profiles change. After four to five passages, the
strain develops stable characteristics again and is then nominated 22F. This conversion from
22A to 22F might be due to a combination of adaptation and selection. Class III strains are
unstable, even in their original mouse genotype and can change their biological characteristics
during just a single mouse passage. Strain 87A is a classical class III strain. 87A was isolated
from six different sheep from four different breeds showing characteristics of 87A. If 87A is
passaged in C57BL mice in low concentrations, it is stable. However, when increasing the
concentration of the prion strain used for inoculation within the same mouse genotype, the
incubation period may be shortened. This newly developed strain was designated 7D. 7D
differs in histopathology from 87A but seems to be identical with the ME7 scrapie strain (Bruce
and Dickinson 1987). Therefore, ME7 might be a modified strain derived from 87A (Beat
Ho¨rnlimann 2007). These findings show, that distinct strains can be observed upon transfer
of prions across a species barrier or into the same species differing in the genotype. This
phenomenon is referred to as a “strain mutation” (Bruce 1993). Cellular cofactors such as
chaperones, specific uptake receptors, RNAs, a certain lipid environment, or a specific prion
replicating subcellular environment, might be involved in the conversion of distinct prion strains
(Aguzzi, Heikenwalder et al. 2007). Since no genetic instructions transmit with the prion to new
hosts, PrPSc must bear information about prion strain structure and propagation (Zabel and
Reid 2015). A possible explanation is, that different conformations are responsible for different
disease strains. Strains might be defined by the tertiary or the supramolecular structure of the
PrPSc (Liebman 2001, Aguzzi 2008). Different prion conformation of distinct prion strains may
vary their ability to cross species barriers (Liebman 2001). The strong species barrier between
mice and hamsters could be due to the difference at 16 of 254 positions between hamster and
mouse PrP, leading to a different protein structure. CWD has not been successfully transmitted
by oral inoculation from infectious material of species other than the cervid family, indicating a
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species barrier for heterologous PrP conversion (Sigurdson 2008, Aguzzi and Calella 2009).
4.6 Prion replication and prionoids
Some investigators claim that prion disease is caused by a virus containing a prion specific
nucleic acid that encodes the information expressed by each infectious extract (Bruce and
Dickinson 1987). But despite the use of a plethora of techniques, no such nucleotide has been
identified to date. Based on the “prion only” hypothesis two models explain the transition from
PrPC into PrPSc and propagation of PrPSc. Historically, prion propagation was believed to oc-
cur through the “refolding” or template assistance model, where exogenously introduced PrPSc
interacts with endogenous PrPC and converts it into further PrPSc. Spontaneous conversion of
PrPC into PrPSc may be prevented by a high activation energy barrier. The activation energy
might be lowered by the formation of PrPSc-PrPC heteroduplexes, facilitating the formation of
further PrPSc from PrPC (Figure 5 a) (Aguzzi and Calella 2009) .The “seeding” or nucleation-
polymerization model proposes that PrPC and PrPSc are in a reversible thermodynamic equi-
librium (Figure 5 b). The position of the equilibrium lies on the side of PrPC, for what reason
only few harmless PrPSc monomers are present. When several monomeric PrPSc molecules
converge into oligomeric seeds, further monomeric PrPSc can be recruited and aggregate to
amyloid. Fragmentation of PrPSc aggregates increases the number of seeds which can re-
cruit further PrPSc. Continued rounds of replication concomitant with ongoing PrPC production
by the host leads to PrPSc accumulation, thereby generating additional transmissible agent
(Aguzzi and Calella 2009, Chakrabarti, Ashok et al. 2009, Knowles, Waudby et al. 2009).
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Figure 5: Models for the conformational conversion of PrPC into PrPSc. a) in the “refolding” or template assistance
model exogenously introduced PrPSc interacts with endogenous PrPC, which is stimulated to transform itself into
further PrPSc. A high energy barrier may prevent spontaneous conversion of PrPC into PrPSc. b) in the “seeding”
or nucleation-polymerization model PrPC and PrPSc are in a reversible thermodynamic equilibrium. Solely if sev-
eral monomeric PrPSc molecules converge into oligomeric seeds, further monomeric PrPSc can be recruited and
aggregate to amyloid. By fragmentation of PrPSc the number of seeds is enhanced, which leads to the recruitment
of further PrPSc, resulting in apparent replication of PrPSc. Reprinted from (Aguzzi and Calella 2009) under the
Creative Commons Attributed License 4.0.
The “seeding” or nucleation-polymerization model, however, is not restricted to PrPSc. When
mice were inoculated with aggregated Amyloid  (A ) seeds, A  was generated de novo and
disease was transmitted (Meyer-Luehmann, Coomaraswamy et al. 2006, Ruiz-Riquelme, Lau
et al. 2018). Lewy pathology was induced when intracerebrally inoculating wild-type mice
with synthetic ↵-synuclein (Luk, Kehm et al. 2012). Two subjects with Parkinson’s disease
provided evidence, that the disease can propagate from host to graft cells. Patients that had
been transplanted with dopaminergic neurons developed ↵-synuclein-positive Lewy bodies in
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grafted neurons (Li, Englund et al. 2008). Experiments showed, that tau pathology resembled
prion pathogenesis in cell-to-cell propagation. Inoculation of Tau aggregates into mice pro-
duced transmissible pathology and tau formed distinct strains (Kaufman, Thomas et al. 2017).
Although the non-classical prions A , ↵-synuclein and Tau show cell-to-cell propagation, one
could certainly argue their transmissibility. Experimental evidence suggests that diseases like
Alzheimer’s and Parkinson’s can be transmitted but are not naturally infectious. Conversely,
several familial diseases caused by PRNP mutations are poorly or non-transmissible and
cause little or no PrPSc accumulation (Tateishi and Kitamoto 1995, Kovacs, Trabattoni et al.
2002). Thus A , ↵-synuclein and Tau were denominated “prionoids” to set them apart from
“true” prions (Ashe and Aguzzi 2013).
4.7 Prion susceptible cell lines
In addition to animal models to investigate prion diseases, there is need for complementary ex-
perimental systems to model aspects of prion diseases (Krejciova, Alibhai et al. 2017). Cellular
cultures supporting prion replication present numerous advantages amongst others shorter in-
cubation time, the ability to analyze biological properties of PrPC and PrPSc at the molecular
and cellular levels, and screening of molecules with potential therapeutic values. To generate
cells that propagate prions, cell cultures are inoculated with infectious brain homogenate and
checked for replication of prions (Solassol, Crozet et al. 2003). In order to obtain cell lines pro-
ducing sufficient amounts of PrPSc, mixed clones are subcloned and the subclones producing
the most of PrPSc selected (Bosque and Prusiner 2000). Upon subpassaging, prion infected
cells are able to promote stable and continuous replication of PrPSc as well as infectivity. To
date, only a small amount of cell culture models capable of prion replication has been gener-
ated. In homologous cell culture models for prion propagation, PrPSc present in the inoculum
and the cultured cells share the same species origin. This approach is thought to omit the
species barrier phenomenon that would reduce the effectiveness of prion propagation, mostly
due to mismatches in primary amino acid sequences of PrP (Solassol, Crozet et al. 2003).
Chesebro and Prusiner generated the first prion infected cells in 1970, infecting mouse neu-
roblastoma N2a cell lines with the murine Rocky Mountain Laboratory (RML) strain (Race,
Fadness et al. 1987, Butler, Scott et al. 1988). A N2a subclone N2a-PK1 (PK1), was later
shown to be highly susceptible to the murine prion strains RML and 22L, but not to ME7, 22A,
mouse-passaged 263K and the BSE-derived 301C (Mahal, Baker et al. 2007). The neuronal
cell line called GT1 established from gonadotropin-releasing hormone neurons immortalized by
genetically targeted tumorigenesis in transgenic mice, is infectable by Chandler, 22L, and 139A
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strains (Schatzl, Laszlo et al. 1997, Nishida, Harris et al. 2000). Repeated subcloning proce-
dure of Cath.a-differentiated (CAD) cells challenging with RML resulted in the CAD-2A2D5 line
(CAD5), which are responsive to RML, 22L, 79A, ME7 and 301C prion strains (Qi, Wang et al.
1997, Klohn, Stoltze et al. 2003, Mahal, Baker et al. 2007, Mahal, Demczyk et al. 2008). Since
PrPSc accumulates mainly in central nervous system cells, neuroblastoma cell lines were cho-
sen for their neuronal phenotype. From various studies conducted with homologous cell culture
models for prion propagation we know, that only some strains could replicate in one particular
cell line. Further only some cells from a cell line can be infected and their susceptibility to
prions is enhanced by subcloning (Bosque and Prusiner 2000, Solassol, Crozet et al. 2003).
PrP expression levels were shown to be important for a successful infection. Transgenic Prnp-
/- mice with extra copies of Prnp (tga20/tga20) show a tenfold increase in PrPC expression
compared to wild type mice such as CD1. tga20/tga20 mice are very susceptible to scrapie
and show much shorter incubation time upon prion infection than CD1 wild type mice (Fis-
cher, Rulicke et al. 1996). Derived from the experience gained in transgenic animals, murine
N2a#58 neuroblastoma cell line overexpressing murine PrP were more readily infected with
three mouse PrPSc scrapie strains Chandler, 139A and 22L compared to N2A cells (Nishida,
Harris et al. 2000). In contrast, another N2A cell line overexpressing PrP (N2a/2M11) was re-
sistant to RML prions, whereas a very susceptible line, N2a/Bos2, was derived from cells that
had been transformed with a control plasmid, and expressed PrP at about the same low level
as the original N2a cells (Enari, Flechsig et al. 2001). Until 2017, there was only one, as yet
unconfirmed, study of direct prion infection of a human immortalized SH-SY5Y neuroblastoma
cell line with CJD prions from a sporadic CJD patient (Ladogana, Liu et al. 1995). In 2017
infection of terminally differentiated astrocytes derived from human induced pluripotent stem
cells (iPSCs) with brain homogenate from human sporadic or variant CJD brain was reported.
The infection was prion protein codon 129 genotype-dependent, meaning vCJD propagated
readily in a line of 129MM astrocytes, but more slowly and less reliably in 129MV and not at all
in 129VV astrocytes. Prions from a sCJD VV2 case replicated faster in 129VV astrocytes than
in 129MM astrocytes. Infectivity could be demonstrated by subpassaging prions from infected
to naive astrocyte cultures (Krejciova, Alibhai et al. 2017). Thus, prion propagation in het-
erologous cell culture models for prion propagation is slower than in homologous cell culture
models. In heterologous models there are either differences between the expressed PrP, or
between the cell line and species origin of the inoculum. A heterologous model for naturally
occurring sheep scrapie was obtained by stable expression of ovine PrP gene and tetracycline
in the rabbit epithelial cell line RK13 (Vilette, Andreoletti et al. 2001). Expression of heterolo-
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gous PrP in the rabbit model show, that nonneuronal cells can replicate prions and the species
barrier can be crossed by the expression of a suitable PrP gene. Heterologous experimental
systems are important to investigate naturally occurring TSE agents. Considering that some
strains can only replicate in one particular cell line, that just a fraction of all cells from a cell
line become infected, most of the time subcloning is needed to enhance the cells susceptibility
to prions, chronically infected cells show lower infectivity titers with increasing cell passages,
and that successful propagation of human CJD in cell cultures has only been reported once,
it is not surprising that many attempts to establish infected cell lines have been unsuccessful
(Elleman 1984, Race 1991, Chesebro, Wehrly et al. 1993).
4.8 Chaperones
Chaperones are involved in the de novo folding of polypeptides, exhibit holding-function, unfold
misfolded proteins, disaggregate aggregated proteins, and convert them into harmless native
proteins or degraded peptides (Figure 6) (Hinault, Ben-Zvi et al. 2006, Finka, Mattoo et al.
2016).
Figure 6: Green: the nontoxic native folding pathway. Black: the toxic non-native misfolding pathway. Red:
Unfolding and disaggregating chaperones use ATP to break apart stable, potentially toxic aggregates and misfolded
oligomers (Reprinted from (Priya, Sharma et al. 2013). License number 4375860575449.
Polypeptides synthesized at the ribosomes exhibit numerous hydrophobic residues, which are
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exposed to the aqueous cytoplasm. Hydrophobic forces drive chain collapse and burial of
non-polar amino acid residues within the interior of the protein. Upon this shaping process the
polypeptide chain reaches a compact globular conformation, termed the native state (Goloubi-
noff 2016). However, hydrophobic collapse can lead to globular intermediates such as partially-
or mis-folded states. Partially folded states can become transiently kinetically trapped. Such
stages must cross substantial free energy barriers during folding to reach again the native
state. Chaperones promote the proper folding of polypeptides and overcome energy barriers
in an ATP-dependent mechanism (Langer, Lu et al. 1992, Frydman, Nimmesgern et al. 1994,
Dunker, Silman et al. 2008). Stressors, such as hypoxia, toxins or heat-shock, may cause par-
tial unfolding, which again leads to exposure of hydrophobic residues and a meta-stable state.
To reach an energetically more stable state, hydrophobic residues can interact within a protein,
leading to misfolded proteins. Interaction between proteins could lead to aggregation. Holding
chaperones prevent in a non-catalytic passive way the aggregation of substrates, that may be
aggregation-prone (Finka, Mattoo et al. 2016). Unfolding chaperones specifically bind exposed
hydrophobic surfaces and unfold misfolded proteins. Following unfolding, some polypeptides
are released to spontaneously refold into the native state (Goloubinoff 2016). Disaggregases
obligatorily use ATP to break apart stable, potentially toxic aggregates by concerted ATP-fueled
motions (Priya, Sharma et al. 2013, Goloubinoff 2016). In addition to molecular chaperones,
cells have evolved the ubiquitin-proteasome system (UPS) and lysosome mediated autophagy
for the degradation of misfolded proteins. Under certain conditions, when chaperones cannot
repair misfolded proteins, overly sticky unfolded polypeptides are degraded via these two path-
ways into small peptides and subsequently by peptidases into amino acids to be reused in de
novo protein synthesis (Muchowski and Wacker 2005, Goloubinoff 2016). Molecular chaper-
ones are classified into six main families on the basis of their approximate molecular mass (in
kDa): HSP100, HSP90, HSP70, HSP60, HSP40 and the small HSPs , which weight less than
40 kDa (Muchowski and Wacker 2005).
4.9 Protein-misfolding disorders and chaperones
Protein-misfolding disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD),
amyotrophic lateral sclerosis (ALS), and prion disease are characterized by the accumula-
tion of intracellular or extracellular aggregates, consisting of misfolded proteins. The proteins
that aggregate in these disorders are unrelated in size or primary amino acid sequence (Mu-
chowski and Wacker 2005). Misfolded proteins are thought to accumulate in neurons and in
other cells as a result of normal ageing, associated with a decrease in proteasome and lyso-
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some activity and dysfunction of molecular chaperones (Muchowski 2002). This might account
for the late onset of neurodegenerative diseases that are linked to protein aggregation (Soti
and Csermely 2002). Recent evidence indicates that chaperones are potent suppressors of
neurodegeneration. In AD, virally mediated overexpression of HSP70 successfully rescues
neurons from the toxic effects of intracellular A  accumulation (Magrane, Smith et al. 2004).
A possible mechanism how cytoplasmic HSP70 protects neurons in this system, might involve
chaperone-stimulated degradation of A  in association with the endoplasmatic reticulum (ER).
In this process misfolded proteins are recognized by a quality control mechanism in the ER,
retro-translocated into the cytosol and degraded by the 26S proteasome (McCracken and Brod-
sky 2003). HSP70 overexpression in a PD model cell line caused a decrease in aggregated
↵-synuclein species and studies in Drosophila melanogaster indicate that HSP70 might have
a protective role in PD (Auluck, Chan et al. 2002, Klucken, Shin et al. 2004). Overexpres-
sion of HSP70 and HSP40 in the presence of mutant SOD1, which aggregates in ALS, in an
N2a (neuroblastoma-like) cell model resulted in reduction of aggregate formation (Takeuchi,
Kobayashi et al. 2002). The yeast Sup35 protein, important for translation termination, is
the analog to mammalian PrPC. [PSI+], a misfolded, self-propagating form of Sup35, is the
mammalian analog to PrPSc and leads to translational read-through. When performing a ge-
netic screen in yeast, 1 out of 6’000 plasmids carrying Hsp104 inhibit nonsense suppression.
Hsp104 is a member of Hsp100 family with ATP-dependent disaggregase function. Interest-
ingly, overexpression or inactivation of Hsp104 causes the loss of [PSI+], whereas yeast prions
under physiological Hsp104 conditions can replicate. Based on the nucleation-polymerization
model, overexpression of Hsp104 enhances its disaggregase function, whereupon all [PSI+]
is in a monomeric, soluble state. If Hsp104 is depleted, all [PSI+] is present in stable aggre-
gates. Without [PSI+] oligomers functioning as seed, there is no [PSI+] replication (Chernoff,
Lindquist et al. 1995). An Hsp104 analog in mammals is not known to date. In addition to
Hsp104, Hsp70 and its Co-Chaperones, as well as Hsp110 interacts with yeast prions too
(Sadlish, Rampelt et al. 2008). So far, interactions of prions and chaperones have mostly
been studied in yeast (Sadlish, Rampelt et al. 2008). Although many studies have shown that
chaperones are protective in models of neurodegenerative disease, the molecular basis of this
protection is not known (Muchowski and Wacker 2005).
4.10 Small interfering RNAs and their application in prion disease
RNA interference (RNAi) protects the eukaryotic genome from invasive nucleic acids such as
viruses, transposons, and transgenes. During the biological mechanism of RNAi a processed
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non-coding RNA forms a single strand RNA-protein complex and induces gene silencing by
targeting complementary mRNA for degradation (Dana, Chalbatani et al. 2017). Long non-
coding double stranded RNA precursors are processed by an endonuclease called Dicer into
short, active (⇠ 20   30 nucleotide) fragments (Figure 7). A short siRNA duplex is loaded
by Dicer and the RNA-binding protein TRBP, onto Argonaute (AGO2) forming an RNA-induced
silencing complex (RISC). The Argonaute protein is the core component of the effector machin-
ery (Carthew and Sontheimer 2009). AGO2 selects the siRNA guide strand, then cleaves and
ejectes the passenger strand. The guide strand subsequently recognizes its complementary
target mRNAs through Watson-Crick base pairing and cleaves it. The cleaved target mRNA is
released and RISC is recycled, using the same loaded guide strand for another few rounds of
cleavage (Jinek and Doudna 2009, Dana, Chalbatani et al. 2017).
Figure 7: 1) Dicer processing of long dsRNA 2) RISC loading 3) Guide-strand selection, passenger strand cleav-
age and ejection 4) Target mRNA recognition and cleavage. Reprinted from (Dana, Chalbatani et al. 2017) under
the Creative Commons Attributed License 4.0.
This mechanism has been revolutionizing the way researchers study gene function in the last
decade. RNAi, first discovered in plants, was later demonstrated in the roundworm Caenorhab-
ditis elegans, and can nowadays be easily applied to mammalian cells by directly transfecting
siRNAs into cells (Dorsett and Tuschl 2004, Dana, Chalbatani et al. 2017). PrPC levels in mice
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correlate with the amount of PrPSc formation and the incubation period. Prnp overexpressing
mice accumulate more PrPSc and show a shorter incubation time than wild type animals (Fis-
cher, Rulicke et al. 1996). Prnp-/- mice are not replicating prions and thus resistant to prions
(Bueler, Aguzzi et al. 1993). Hemizygous Prnp+/- mice show longer incubation periods when
compared to wild type animals (Bueler, Raeber et al. 1994, Manson, Clarke et al. 1994). The
same picture holds true when PrP levels are reduced by siRNAs targeting Prnp in infected
cell cultures. Both the normal host prion protein and PrPSc are depleted in murine PrP over-
expressing N2a#58 cells chronically infected with the Chandler strain as well as in GT1 cells
infected with the 22L strain. The knock down efficiency of the Prnp targeting siRNAs was not
influenced by different murine-adapted scrapie strains or different cell lines (Daude, Marella et
al. 2003). An siRNA delivery system consisting of a small peptide binding siRNA and acetyl-
choline receptors, targets the siRNA specifically to acetylcholine receptor expressing cells and
reduces PrPC and PrPSc levels in N2a cells. Cationic liposomes injected intravenously into
mice protected siRNA-peptide complexes from serum degradation (Pulford, Reim et al. 2010).
RNAi targeting Prnp was applied to prion therapeutics in mice. Lentiviral delivery of a shRNA
targeting Prnp reduced PrP levels and prolonged survival time (Pfeifer, Eigenbrod et al. 2006,
White, Farmer et al. 2008). The robustness of the RNAi approach has motivated numerous
groups to conduct genome-wide screens in mammalian cells to identify and validate potential
drug targets. Thus, identifying genes involved in the modulation of PrP levels by RNAi screens
represents a promising approach for prion therapeutics. However, one must be aware and test
for the potential induction of non-specific and sequence-specific off-target effects of siRNAs
(Fire, Xu et al. 1998, Dorsett and Tuschl 2004, Dana, Chalbatani et al. 2017).
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5 Aims of the thesis
For my thesis I proposed to shed light on the factors involved in misfolding from physiological
PrPC to misfolded PrPSc or potential un-folding of PrPSc by identifying chaperones, that are
involved in PrPC biosynthesis and PrPSc replication by siRNA mediated screens. I planned to
screen the entire mammalian repertoire of chaperones, e.g. the “chaperome” in a plenary and
unbiased approach. Because chaperones collaborate with one or two co-chaperones to com-
pensate functional failure, I planned to simultaneously knock down two or three chaperones,
after having evaluated single knockdown screens. I opted for PrPC and PrPSc levels as read-
outs, measured in two distinct screens on two fully automated robotic platforms. I proposed to
analyze experimental data with a customized software and to validate hits with other siRNA or
CRISPR-Cas9 in other cell types, such as primary neurons or iPSC-derived human neurons
available in our lab. Upon thorough network analysis of validated hits, I aimed to formulate
testable hypotheses on a potential involvement of chaperones in the machinery involved in
PrPC biosynthesis and PrPSc replication. To achieve these exciting goals, I structured my PhD
project in four major objectives (Figure 8).
Objective 1: Establish siRNA screens targeting chaperone genes in murine cells with PrPC
and PrPSc levels as readout. I aim to detect chaperones, that are involved in the posttransla-
tional folding processes of PrPC by applying the murine cell-based homogeneous-phase bioas-
say established in our lab. I further plan to establish a PrPSc screen with RML6 infected neu-
ronal cells on a LabCyte acoustic dispensing robot for 384-well plate format and Perkin-Elmer
Janus liquid handling platform.
Objective 2: Generate a murinized human cell line susceptible to murine prions. Establish
an siRNA screen targeting chaperone genes in human murinized cells with PrPC and PrPSc
levels as readout. By utilizing a human cell line as model system, I aim to identify human
chaperones potentially involved in the cellular prion protein replication machinery. Cells suit-
able for the human PrPC and PrPSc chaperone screens need to meet four requirements: 1) A
PRNP knockout version of my cell line of interest as negative control, 2) for the human PrPC
screen, the cell line needs to express sufficient amounts of PrPC for clear discrimination of
controls transfected with scrambled siRNA and siRNA targeting PRNP, 3) to minimize the risks
that arise when working with prion-infected human cells, a murinized version of the cell line is
required for the human PrPSc screen, 4) finally, the murinized version should be susceptible to
murine prions, ideally to RML6, which is prominently used in our lab.
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After the generation of a suitable murinized cell line, I plan to run the human chaperone screen
with siRNAs targeting the same chaperone transcripts as in the murine screen.
Figure 8: Project overview
Objective 3: After completing the murine and human PrPC and PrPSc screens, I purpose to
compare the hits to contrast the effect of chaperones on PrP levels in two different mammalian
experimental systems. I subsequently plan to validate potentially therapeutic chaperones.
Objective 4: Upon network analysis of validated chaperone hits, I plan to formulate hypotheses
on a potential involvement of chaperones in the biosynthesis of the prion protein and in the
murine prion protein replication machinery.
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6 Results
6.1 Chaperone siRNA screens in murine cells
6.1.1 siRNA preparation
Prof. Pierre Goloubinoff, (University of Lausanne, CH) provided me with a list of the entire
mammalian repertoire of chaperones, e.g. the “chaperome” consisting of 240 chaperones. He
selected 31 chaperone-pairs for double knockdown, based on the expression of co-chaperones
in the same cellular compartments and known interactions. I performed the screens with two
different siRNA libraries. The first arrayed druggable mouse siRNA library provided by Novartis
contained 376 siRNAs against 99 transcripts of druggable chaperones, that were actually ex-
pressed in CAD5 cells based on a CAD5-RNASeq data set (13’752 expressed genes). Each
gene was targeted by two up to four different siRNAs. The second library consisted of 560
siRNAs against 140 non-druggable chaperone transcripts, including transcripts that were not
expressed in CAD5 cells. In this arrayed mouse siRNA library purchased at ThermoFisher,
one gene was targeted by 4 different siRNAs. Because the DNA sequence of one chaperone
was not available, no suitable siRNAs could be synthesized and totally 239 chaperones were
screened. A scrambled non-target siRNA and an siRNA targeting the prion protein gene were
used as negative and positive controls. The final concentration of siRNA per well was 30nM.
For the double knockdown screen, I found the best cell viability and knockdown efficiency at a
final concentration of 30nM for two pooled siRNAs per well (Figure 9).
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Figure 9: Cells transfected with individual Prnp targeting siRNA and scrambled siRNA or a 1:1 mixture of both
siRNAs with concentrations from 30 nM – 60 nM. Untransfected cells (UT) served as control. a) the cell viability of
CAD5 wild type (wt) cells decreased with increasing siRNA concentrations, except when transfecting Prnp targeting
siRNA only. b) PrP levels depicted as Net-FRET levels showed no PrP in untransfected CAD5 Prnp-/- cells (KO
UT) generated in our lab by CRISPR-Cas9 technology. PrP expression in untransfected CAD5 wt cells (wt UT) was
high. All siRNA concentrations with pooled Prnp targeting siRNA and scrambled siRNAs led to the same reduction
of PrP levels.
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6.1.2 Murine PrPC screen
I applied and advanced the murine cell-based homogeneous-phase bioassay established in
our lab (Figure 10), to screen for chaperones that affect PrPC levels (Li 2016).
Figure 10: Workflow PrPC screen.
Sample siRNAs targeting chaperone transcripts and control siRNAs were printed with an Echo
Acoustic Liquid Handling technology in 384-well microtiter plates on the fully automated robotic
LabCyte platform. The acoustic dispenser allowed contactless transfer of siRNAs according
to a randomized plate layout (Appendix 79). The sophisticated plate layout was designed to
compensate eventual plate gradients or biological variability within technical replicates in order
to get real positive hits. The plates containing printed siRNAs were frozen until the assay day,
when Lipofectamine RNAiMAX reagent and 2800 CAD5 cells per well are added for reverse
transfection by Biotek MultiFlo FX dispenser within the Perkin-Elmer Janus liquid handling
platform. CAD5 cells are prion-susceptible cells, derived from neuronal Cath.a-differentiated
(CAD) cells (Qi, Wang et al. 1997). In addition to CAD5 treated with siRNA controls, CAD5
Prnp-/- cells generated in our lab by CRISPR-Cas9 technology, were used as negative control.
After 24 hours, cell viability marker Real Time Glo (RT-Glo), measuring the reducing potential
and metabolism of cells was added. After 72 hours of incubation, RT-Glo cell viability and PrP
levels were assessed with the Envision reader. RT-Glo signals were used to define thresholds
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for extreme low or high cell viability and could be used in the analysis of the PrP levels to select
chaperones altering the PrP metabolism rather than cell viability. PrP levels were assessed by
homogeneous-phase fluorescence resonance energy transfer (HP-FRET) assay. FRET was
based on the energy transfer between two fluorophores, Europium (Eu3+) and Allophycocyanin
(APC), which were separately labelled to the anti-PrP antibodies POM1 and POM19 targeting
alpha helices 1 and 3 in the globular domain of PrP less than 10 nm apart from each other (Fig-
ure 11 a) (Polymenidou, Moos et al. 2008). When Eu3+ and APC labelled anti-PrP antibodies
bound to a single PrP molecule, the excited donor Eu3+ transferred energy to the acceptor APC
by non-radiative dipole-dipole coupling, which emitted photons as fluorescence that could be
measured at 665 nm (Figure 11 b).
Figure 11: a) Europium (Eu3+) and allophycocyanin (APC) separately labelled to the anti-PrP antibodies POM1
and POM19 targeting alpha helices 1 and 3 in the globular domain of PrP. Image courtesy Bei Li. b) Energy transfer
from the donor Europium coupled to POM19, to the acceptor APC coupled to POM1 less than 10 nm apart from
each other.
I performed a test screen with two plates containing CAD5 wild type (wt) and CAD5 Prnp-
/- cells, transfected only with control, but no sample siRNAs. Since the test screen passed
quality control, I did run the first murine single knockdown (SKD) PrPC screen using an siRNA
library targeting druggable chaperones in four 384-well plates. Raw data files from the Envision
reader with data from cell viability (RT-Glo luminescence) and PrP levels (FRET Fluorescence)
were exported and fed into a custom-written online software. Experimental data and quality
controls (QC) were automatically pulled together in RMarkdown documents. Net-FRET data
representing PrP levels were visualized in heatmaps for all four screen plates (Figure 12).
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Figure 12: Net-FRET levels representing PrPC levels were visualized for four plates as heatmaps. High PrP levels
were depicted in orange, low PrP levels in blue. CAD5 Prnp-/- cells in every second well in columns one and two
showed low Net-FRET levels around 75’000 depicted in dark blue. Cells transfected with Prnp siRNA controls
showed Net-FRET levels around 125’000 depicted in dark orange. Non-target siRNA treated controls showed
Net-FRET levels above 150’000 depicted in bright orange. Samples showed different Net-FRET levels.
To calculate Net-FRET, the APC background fluorescence and detection buffer were subtracted
from the raw FRET signal of each sample in APC and Eu channels (equation 1). Spectral
overlap compensation was measured by the proportionality factor P (equation 2) (Ballmer,
Moos et al. 2017). The first QC of PrPC levels in the form of Net-FRET signal showed distinct
separation between the control groups (Figure 13).
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Figure 13: Net-FRET quality controls from the first PrPC SKD screen. Each histogram represented one plate.
CAD5 Prnp -/- control (blue), Prnp targeting siRNA control (green), and non-target siRNA control (orange) were
clearly separated from each other. Samples (violet) were distributed between the Prnp targeting and scrambled
siRNA controls.
Strictly standardized mean difference (SSMD), which is commonly used for QC in screening,
was defined for a moderately strong control. SSMD calculated for Net-FRET values of non-
target siRNA and Prnp targeting siRNA controls as well as for non-target siRNA and CAD5
Prnp-/- cells were in the excellent range and thus passed quality control (Figure 14) (Bosque
and Prusiner 2000).
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Figure 14: SSMD calculated for Net-FRET values of non-target siRNA and Prnp targeting siRNA controls were
in the excellent range (left). SSMD calculated for Net-FRET values of non-target siRNA control and CAD5 Prnp-/-
cells were in the excellent range too (right).
The QC of cell viability in the form of heatmaps representing the RT-Glo signal showed an
overall gradient with decreasing signal from plate four to one (Figure 15).
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Figure 15: RT-Glo luminescence levels representing cell viability levels were visualized for four plates as heatmaps.
High RT-Glo luminescence signal standing for high cell viability was depicted in orange, low RT-Glo levels in blue.
QC of RT-Glo luminescence signal showed overall and inter-plate temperature gradients.
The overall gradient correlated with temperature, which could be explained by the order of plate
measurement. Plate four which showed the highest RT-Glo signal was measured as first plate.
Plate four was directly taken out of the incubator at 37 C and measured at room temperature.
Meanwhile the other plates were cooling down at room temperature, which was reflected in
progressively lower RT-Glo levels with lowest levels in plate one, which was measured as last
plate. The outermost control wells showed low RT-Glo levels, which could be explained by
cooling starting from the boarders, which resulted in an additional inter-plate temperature gra-
dient. The outermost wells, which were prone to evaporation, were excluded from further data
analysis. Consistent with the heat map, a swarm blot depicting the RT-Glo luminescence of the
controls for each plate showed lower RT-Glo values in Plate 1 than in the other plates (Figure
16 a). The variability of the cell viability was high, however, the siRNA controls overlapped in
the same range (Figure 16 b). CAD5 Prnp-/- cells, that were seeded only in the first two rows
clustered closely in the middle of the swarm blot. The samples were within the the range of the
controls with a slightly lower viability than the controls.
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Figure 16: Cell viability QC. a) Swarm blot depicting the RT-Glo luminescence of the controls for each plate. One
dot represented one well of CAD5 wt cells either transfected with non-target siRNA, Prnp targeting siRNA or CAD5
Prnp-/- cells. RT-Glo levels were reduced in plate 1. b) Histogram showing the overlap in cell viability of the controls
and samples.
QC of Net-FRET further included checking for row or column effects on the plate that could
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arise with unequal dispensing and cause inter-plate variability. The mean value of odd and
even columns over plates one to four was more even than for odd and even rows, but both
were in the acceptable range (Figure 17).
Figure 17: Quality controls of the first PrPC SKD screen checking the mean value over plates 1 – 4 for odd and
even rows and columns. The variability in rows was higher than within columns, but still in the acceptable range.
Higher variability between rows could be explained by the dispensing pattern of the dispenser. Two subsequent
rows were filled by the same tip of the cassette within the dispenser, whereas one column was filled by eight
different tips. The differences within columns caused by eight tips are likely to neutralize each other, resulting in
lower variability.
To allow comparison and combination of data from different plates in the screen, the Net-FRET
values were normalized by Gaussian process prediction. For each plate, the Gaussian process
with the best fit was chosen by lowest Bayesian information criterion to model the data (Figure
18) (Birmingham, Selfors et al. 2009, Wit, van den Heuvel et al. 2012).
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Figure 18: Best fit Gaussian process prediction based on Net-FRET values for plates 1 – 4 of the first PrPC SKD
screen.
Replicate correlation was calculated by robust linear regression applied to the raw Net-FRET
signal of duplicates and to Gaussian process normalized net-FRET signal. The coefficient of
determination for raw Net-FRET was r2 = 0.424, r2 for Gaussian process normalized Net-FRET
signal was 0.467 (Figure 19).
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Figure 19: a) Robust linear regression of the raw net-FRET signal of duplicates with coefficient of determination
r2 = 0.424. b) Robust linear regression of the Gaussian process normalized net-FRET signal of duplicates with
coefficient of determination r2 = 0.467.
Due to the gradients in RT-Glo signals caused by differences in temperature, normalization of
the Net-FRET signal with RT-Glo cell viability reduced the correlation between technical repli-
cates in most of the cases. Therefore, I decided to implement the RT-Glo data manually. Hits
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were selected based on the best gaussian processed normalized sample signal versus non-
target comparison at a threshold p = 0.001. Of total 376 siRNAs, 82 siRNAs led to substantial
downregulation of PrP levels. The library comprised multiple siRNAs against each target. The
two top hits Hspa5 and Psmc5, were both targeted by four siRNAs (Figure 20). Seven chap-
erones were targeted by three siRNAs, 12 chaperones by two siRNAs. 27 chaperones were
targeted by one siRNA. The proteomic composition of the neuronal CAD5 cells was char-
acterized, herein 4142 proteins, representing 96.8% of the total mass of polypeptides, were
quantified significantly above the back-ground noise, out of 8403 protein identifications. The
quantitative values as mass fractions and copy number per cubic micron were implemented
into the chaperone hit characterization. Chaperone hits that were targeted by the RNAi screen
but that were undetectable or not significantly quantified in the proteomics experiment, were
high-lighted in red.
Figure 20: Druggable chaperone hits from the first PrPC SKD screen reducing the PrP signal. The two top hits
Hspa5 and Psmc5, were both targeted by four siRNAs (yellow). Seven chaperones were targeted by three siRNAs
(dark orange), 12 chaperones by two siRNAs (bright orange). 27 chaperones were targeted by one siRNA (blue).
Chaperone hits that were targeted by the RNAi screen but that were undetectable or not significantly quantified in
the proteomics experiment, were high-lighted in red.
I performed the second murine SKD PrPC screen with an arrayed siRNA library targeting non-
druggable chaperones in six 384-well plates. Net-FRET data representing PrP levels were
visualized in heatmaps for all six screen plates (Figure 21).
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Figure 21: Net-FRET levels representing PrPC levels were visualized for six plates as heatmaps. CAD5 Prnp-/-
cells in every second well in columns one and two showed low Net-FRET levels below 5000 depicted in black.
Cells transfected with Prnp siRNA controls showed Net-FRET levels between 5000 and 10’000 depicted in dark
blue. Non-target siRNA treated controls showed Net-FRET levels between 10’000 and 20’000 depicted in violet
and orange. Samples showed different Net-FRET levels.
QC of PrPC Net-FRET signal showed distinct separation between the non-target and Prnp
siRNA control groups (Figure 22).
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Figure 22: Net-FRET quality controls from the second PrPC SKD screen. Each histogram represented one plate.
CAD5 Prnp -/- control (blue), Prnp targeting siRNA control (green), and non-target siRNA control (orange) were
clearly separated from each other. Samples (violet) were distributed around scrambled siRNA controls.
SSMD defined for a moderately strong control calculated for Net-FRET values of non-target
siRNA and Prnp targeting siRNA controls were in the excellent and good range (Figure 23)
(Bosque and Prusiner 2000). SSMD for non-target siRNA and CAD5 Prnp -/- controls were in
the excellent range.
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Figure 23: SSMD calculated for Net-FRET values of non-target siRNA and Prnp targeting siRNA controls of plates
1, 2, 3 and 5 were in the excellent range, plates 4 and 6 in the good range (left). SSMD calculated for Net-FRET
values of non-target siRNA control and CAD5 Prnp-/- cells were in the excellent range for all plates (right).
In the second screen I acclimatized the plates for one hour to room temperature, before mea-
suring the RT-Glo luminescence cell viability signal with the Envision reader. QC in the form
of heatmaps representing the cell viability showed that the RT-Glo luminescence signal was
much more homogeneous than in the first screen (Figure 24).
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Figure 24: RT-Glo levels representing cell viability were visualized for four plates as heatmaps. Low RT-Glo levels
around 200’000 were depicted in blue, medium RT-Glo levels around 400’000 were shown in dark orange, and high
RT-Glo levels above 600’000 were shown in bright orange.
A swarm blot depicting the RT-Glo luminescence of the controls for each plate showed com-
parable viability between plates and separation between the different controls (Figure 25 a).
CAD5 Prnp-/- cells showed the highest variability, followed by Prnp transfected cells. Non-
target siRNA led to the lowest viability. The range of the cell viability was much smaller than in
the first screen. The samples were within the range of the controls (Figure 25 b).
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Figure 25: Cell viability QC. a) Swarm blot depicting the RT-Glo luminescence of the controls for each plate. One
dot represented one well of CAD5 wt cells either transfected with non-target siRNA, Prnp targeting siRNA or CAD5
Prnp-/- cells. RT-Glo levels differed between the controls. b) Histogram showing the overlap in cell viability of the
controls with slightly enhanced viability in some samples.
QC for row or column effects on the plate was comparable between rows and columns and
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was in the acceptable range (Figure 26).
Figure 26: Quality controls of the second PrPC SKD screen checking the mean value over plates for odd and even
rows and columns. The variability in rows was comparable to columns and in the acceptable range for all six screen
plates.
The Net-FRET values of each plate were normalized by Gaussian process prediction (Figure
27) (Birmingham, Selfors et al. 2009, Wit, van den Heuvel et al. 2012).
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Figure 27: Best fit Gaussian process prediction based on Net-FRET values of the second PrPC SKD screen.
Replicate correlation was calculated by robust linear regression applied to the raw Net-FRET
signal of duplicates and to Gaussian process normalized net-FRET signal. The coefficient of
determination for raw Net-FRET was r2 = 0.125, r2 for Gaussian process normalized Net-FRET
signal was 0.16 (Figure 28).
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Figure 28: a) Robust linear regression of the raw net-FRET signal of duplicates with coefficient of determination
r2 = 0.125 b) Robust linear regression of the Gaussian process normalized net-FRET signal of duplicates with
coefficient of determination r2 = 0.16.
Hits were selected based on the best gaussian processed normalized sample signal versus
non-target comparison at a threshold p = 0.001. Of total 560 siRNAs, one siRNA targeting
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Psmd11 led to significant downregulation of PrP levels, 24 siRNAs to upregulation. 22 chap-
erones were targeted by one siRNA, chaperones Hsf1 and Chordc1 were targeted by two
siRNAs, leading to elevated PrP levels (Figure 29). Chaperone hits that were targeted by
the RNAi screen but that were undetectable or not significantly quantified in the proteomics
experiment, were high-lighted in red.
Figure 29: Non-Druggable chaperone hits from the second PrPC SKD screen increasing the PrP signal. 2 chaper-
ones were targeted by two siRNAs (bright orange), 22 chaperones were targeted by one siRNA (blue). Chaperone
hits that were targeted by the RNAi screen but that were undetectable or not significantly quantified in the pro-
teomics experiment, were high-lighted in red.
The libraries of the two PrPC screens comprised multiple siRNAs against each target. Enrich-
ment of these multiple siRNAs against a specific target facilitated the discrimination between
true and false positives. I selected true positive chaperone hits according to the number of siR-
NAs present in siRNA hits, targeting the same chaperone. I considered chaperones targeted
by more than one siRNA as true positive hits, if they were within the viability range (Figure 30).
The viability range was defined by the mean of non-target controls +/- 2 SD. I analyzed the
viability for each gene with all siRNAs in technical duplicates (Appendix 80 + 81). If more than
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half of the siRNAs targeting the same gene were within the viability range, the gene passed
viability QC. Gene and protein names of chaperone hits that were targeted by two, three and
four siRNAs were summarized in a table with indication of up- or downregulating effect on PrP
(Figure 30). All of these hits passed the viabilty QC.
Figure 30: Gene and protein names of all chaperone hits from the first and second PrPC SKD screen of chaperone
hits that were targeted by four (yellow), three (dark orange) and two siRNAs (bright orange). Chaperones leading
to downregulation of PrP were marked in bright claret-red, hits leading to upregulation of PrP in dark claret-red.
Chaperone hits that were targeted by the RNAi screen but that were undetectable or not significantly quantified in
the proteomics experiment, were high-lighted in red.
6.1.3 Murine PrPSc screen
For the murine PrPSc screen I first established acute infection of cells with subsequent PK-
Western blotting by optimizing existing protocols from the literature for CAD5 cells (Vorberg,
Raines et al. 2004, Greil, Vorberg et al. 2008). I inoculated CAD5 wild type (wt) and Prnp-/-
cells for 96 hours with infectious brain homogenate from mice inoculated with RML6 and non-
infectious brain homogenate (NBH) (0.3 and 0.1 µg/mL). I washed the samples four times to
remove residual inoculum. Subsequently, I lysed the samples, digested them with Proteinase
K (PK) and performed Western blotting. PK-Western blots showed, that RML6 containing brain
homogenate, which served as positive control, exhibited the typical diagnostic shift towards a
smaller PK-resistant core with un-, mono- and di-glycosylated PrPSc (Figure 31). PrPC from
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uninfected and NBH treated CAD5 cells, which both served as negative controls, was com-
pletely digested. CAD5 cells infected with 0.3 µg RML6/mL did show a stronger PrPSc band
than cells infected with 0.1 µg RML6/mL. Despite the four washing steps there was some resid-
ual RML6 inoculum in the CAD5 Prnp-/- cells. The PrPSc band of infected CAD5 wt cells was
much stronger than in CAD5 Prnp-/- cells, indicating replication of PrPSc.
Figure 31: PK-Western with acutely infected CAD5 wt, and CAD5 Prnp-/- cells. CAD5 cells were successfully
infected with RML6 by acute infection as shown by the typical shift of PK-digested RML6 with un-, mono- and
di-glycosylated PrPSc bands. Chronically infected scCAD cells digested with PK showed reduced levels of PrPSc
when inoculated with lower RML6 concentrations (0.1µg). RML6 brain homogenate served as a positive control
(first and second band). Uninfected and NBH treated CAD5 cells, as well as CAD5 Prnp-/- cells digested with PK
served as negative controls and did not show residual PrPC.
Based on the PK-Western results and on a HP-FRET protocol that had been established previ-
ously in our lab, I performed the PrPSc screen with acute CAD5 cell infection in 384-well format
(Li 2016). siRNAs were printed on a LabCyte acoustic dispensing robot into 384-well plates
and frozen at -40 C (Figure 32). At the assay day the plates were thawed, Lipofectamine and
2800 CAD5 cells were added. After 24 hours infectious medium containing RML6 and RT-
Glo cell viability marker were added. After 96 hours the cell viability was assessed with the
Envision reader. In contrast to PrPC, PrPSc is relatively Proteinase K (PK) resistant. PrPC
was completely digested by adding Protinase K (PK) to the lysis buffer. PK was inactivated by
Phenylmethanesulfonyl (PMSF). Denaturation buffer (0.5M NaOH) disassembled PK-resistant
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PrPSc aggregates into monomers and made epitopes available for the FRET-antibodies. Neu-
tralizing buffer (0.5M NaH2PO4) was added to bring the pH to the physiological range, where
the FRET antibodies were not degraded (Peretz, Scott et al. 2001). PrPSc levels were as-
sessed by HP-FRET.
Figure 32: Workflow of PrPSc screen with reverse transfection and acute infection of CAD5 cells. After 96 hrs
the cell viability was assessed with the Envision reader. Subsequently, the cells were lysed and digested with PK
to remove PrPC. PK was inactivated by Phenylmethanesulfonyl (PMSF). Denaturation buffer (0.5M NaOH) dis-
assembled PK-resistant PrPSc aggregates into monomers and made epitopes available for the FRET-antibodies.
Neutralizing buffer (0.5M NaH2PO4) was added to bring the pH to the physiological range, where the FRET anti-
bodies were not degraded. PrPSc levels were assessed by HP-FRET.
To acutely infect CAD5 wt and CAD5 Prnp-/- cells, I used inoculum concentrations ranging
from 1 µg/mL to 0.05 µg/mL of RML6 and NBH brain homogenate. The Net-FRET results did
not show significant difference between the two infected cell types (Figure 33).
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Figure 33: HP-FRET with CAD5 wt (wt) and CAD5 Prnp-/- cells (KO) acutely inoculated with different dilutions of
RML6 and NBH ranging from 1 µg/mL to 0.05 µg/mL. Cells treated with NBH and untreated (UT) cells served as
negative controls. Net-FRET signals standing for PrPSc levels showed no significant difference between CAD5 wt
and CAD5 Prnp-/- cells.
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Most probably residual inoculum masked endogenous prion replication. To reduce the con-
centration of the inoculum and still detect the PrPSc signal, I established an Enzyme-linked im-
munosorbent PrPSc assay (PrPSc-ELISA). After PK digestion, denaturation and neutralization,
I transferred the PrPSc samples to ELISA plates that I had previously coated with PrP-binding
POM1 antibody in PBS at 4 C overnight and blocked with 5% SuperBlock. I used Biotinylated
POM19 anti PrP antibody and Streptavidin-HRP to detect PrPSc. PrPSc-ELISA was sensitive
enough to distinguish the 10 5 dilution of RML6 from the blank (Figure 34 a). PrPSc-ELISA with
PK undigested recombinant murine PrP (rmPrP22-230) showed, that samples with concentration
between 0.63 and 0ng/mL were in the linear range of the ELISA (Figure 34 b).
Figure 34: PrPSc-ELISA with 1:2 dilutions of infectious RML6 brain homogenate digested with PK. ELISA ab-
sorbance stands for PrPSc levels. PrPSc-ELISA was sensitive enough to distinguish the 10 5 dilution of RML6 from
the blank. b) PrPSc-ELISA with 1:2 dilutions of recombinant murine PrP (rmPrP22-230). ELISA absorbance stands
for PrPC levels. Samples were in the linear range of the ELISA when their concentration was between 0.63 and 0
ng/mL.
When I acutely infected CAD5 cells with very low concentrations of RML6 (0.03 – 0.008 µg/mL)
PrPSc-ELISA showed that PrPSc levels were higher in inoculated cells than in the inoculum with
0.03 and 0.0016 µg RML6 per mL, but not anymore with 0.0008 µg RML6 per mL (Figure 35).
The masking effect was still apparent and there was no clear distinction between infected
CAD5 wild type (wt) and CAD5 Prnp-/- cells acutely infected with RML6.
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Figure 35: PrPSc-ELISA with CAD5 wt (wt) and CAD5 Prnp-/- cells (KO) acutely inoculated with different dilutions
of RML6 and NBH. PrPSc-ELISA absorbance signals standing for PrPSc levels did not show clear distinction between
CAD5 wt and CAD5 Prnp-/- cells. Cells treated with NBH and untreated (UT) cells served as negative controls and
showed that PK digestion of PrPC was complete.
In order to remove residual inoculum, I generated chronically infected scCAD cells by inoculat-
ing CAD5 cells with 0.1 µg/mL RML6 and non-infectious brain homogenate (NBH). I removed
the medium containing the inoculum after 3 days and split the cells four times 1 : 5 every 3 – 4
days (Figure 36).
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Figure 36: Scheme of chronical infection. I inoculated CAD5 cells with 0.1 µg/mL RML6 and NBH. After three
days I removed the medium containing the inoculum and split the cells four times 1 : 5 every 3 – 4 days. After the
fourth splitting, I lysed the cells and performed PK-Western blotting.
I generated CAD5 cells overexpressing PrP by stable transfection of CAD5 Prnp-/- clone #C12
with the coding region of murine Prnp and clonal selection through limited dilution. Sandwich
ELISA of these cells showed that multiple, random integration of murine Prnp into the murine
genome driven by the strong (Cytomegalovirus) CMV promoter led to significantly higher ex-
pression of murine PrP in three isolated clones (#6, #9 and #11), than in CAD5 wild type and
CAD5 Prnp -/- clones (Figure 37 a). Immunohistochemistry of clone #9 (hyCAD) revealed
physiological membranal expression of murine PrP (Figure 37 b).
Figure 37: (Description on the next page)
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Figure 37: Characterization of CAD5 cells overexpressing PrP, which I generated by stably transfecting CAD5
Prnp-/- cells with the coding region of murine Prnp. Clonal selection through limited dilution resulted in three
clones #6, #9 and #1. a) Sandwich ELISA with absolute PrP values showed significantly higher PrP levels in
the three clones than in CAD5 wt. Clone #9 showed the highest PrP expression. Absolute PrP values were
interpolated from the linear range of the calibration curve with rhPrP22-231. PrP overexpressing CAD5 clones
were individually compared to CAD5 wild type. *** p ¡ 0.001, unpaired, two-tailed T-test. b) Confocal microscopy
images of immunostaining of PrP with POM1 or POM19 antibody in #9 (hyCAD) showed physiological expression
of PrP at the membrane. CAD5 Prnp-/- cells did not show any PrP. Scale bar 10 µm.
I chronically infected as well PrP overexpressing CAD5 clone #9 (hyCAD) with RML6 prions
(scHyCAD). I lysed the chronically infected scCAD and scHyCAD cells and digested them with
Proteinase K (PK) before Western blotting. PK-Western showed complete digestion of PrPC by
PK in untreated and NBH treated CAD5 cells, which both served as negative controls (Figure
38). RML6 containing brain homogenate, which served as positive control, as well as RML6
infected CAD5 and hyCAD cells, exhibited the typical diagnostic shift towards a smaller PK-
resistant core with un-, mono- and di-glycosylated PrPSc. hyCAD cells chronically infected with
RML6 showed higher levels of PrPSc than CAD5 cells. No residual inoculum was detectable in
CAD5 Prnp-/- cells.
Figure 38: PK-Western with CAD5 wt and hyCAD chronically infected with RML6 show the typical diagnostic shift
towards a smaller PK-resistant core with un-, mono- and di-glycosylated PrPSc. PK digestion of PrPC in in untreated
and NBH treated CAD5 cells was complete. There was no residual inoculum in RML6 infected CAD5 Prnp-/- cells.
I assessed cell growth of scCAD, CAD5 wt and CAD5 Prnp-/- with IncuCyte ZOOM live-cell
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analysis system. I seeded cells in increasing concentrations into 384-well plates imaged the
cells every 12 hrs for totally 160 hours. I quantified the confluence with the IncuCyte ZOOM
software. CAD5 wt and Prnp-/- reached confluence at 72 or 80 hours respectively, with all cell
seeding numbers (Figure 39). scCAD cells reached confluence at 72h, when seeding   2500
cells per well.
Figure 39: Quantification of the cell growth (confluence %) of different numbers (2000 – 4000 per well of 384-well
plates) of CAD5 wt, CAD5 Prnp-/- and scCAD cells with IncuCyte ZOOM live-cell analysis system. CAD5 wt and
Prnp-/- reached confluence at 72 or 80 hours respectively, with all cell seeding numbers. scCAD cells reached
confluence at 72h, when seeding   2500 cells per well. The cells were imaged every 12 hours for totally 160
hours.
Since scCAD cells reached confluence at 72h, when seeding   2500 cells per well, I could
perform the PrPSc assay within 72 hours, within the activity window of siRNAs. Compared
to the PrPSc assay with acute infection, chronical infection shortened the incubation time by
24 hours and the cell population was more homogeneous. I performed PrPSc-FRET with cell
lysate of scCAD inoculated with two different concentrations of RML6 (10-2 and 10-3) from
two different passages (P12 and P18) (Figure 40). Net-FRET signals minus blank showed
complete digestion of PrPC in CAD5 wt and CAD5 Prnp-/- (KO), which served as negative
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controls. PrPSc levels were reduced in scCAD cells inoculated with lower RML6 concentrations
and with higher passages. Net-FRET signals minus blank of infected scCAD was sufficiently
distinguishable from the negative controls with concentrations of 40 and 30 µg total protein. I
found the actual total protein concentration per well with living cells was 3 to 5 µg per well.
Figure 40: PrPSc-FRET with chronically infected scCAD5 lysate showed, that the PrPSc signal was significantly
higher or clearly distinguishable from in CAD5 wt and CAD5 Prnp-/- (KO), which served as negative controls, with
40 and 30 µg total protein. These concentrations were one log higher than the actual protein concentration within
one well with living cells.
The results with cell lysate of scCAD showed, that HP-FRET was not sensitive enough to
detect the difference between living uninfected wild type CAD5 and chronically infected scCAD
by one log. When I tested different PK concentrations lower than the established 5 µg per mL,
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to increase the signal, PrPC digestion was incomplete (Figure 41).
Figure 41: PrPSc-FRET with 40 µg chronically infected scCAD5 lysate digested with 1 to 4 µg of PK/mL showed
incomplete digestion of PrPC. Complete digestion of PrPC would show equal Net-FRET levels of CAD5 wt and
Prnp-/- (KO) cells.
The signal could be enhanced by reducing the PK concentration, however digestion of PrPC
was incomplete. To detect low PrPSc signals I performed PrPSc-ELISA with chronically infected
scCAD cells, that I had forward transfected with 30nM of Prnp targeting and scrambled non-
target siRNAs for 72 hours (Figure 42 a + b). Despite high inter-well variability, PrPSc levels
were significantly reduced by Prnp siRNA compared to the scrambled siRNA control. When I
performed the same assay with reverse transfection on the LabCyte acoustic dispensing robot,
inter-well variability was higher and the difference between Prnp siRNA and scrambled siRNA
treated cells was less distinct than with manual forward transfection (Figure 42 c + d). PrPC
digestion by PK was complete in both assays. The samples digested with PK were on the
lower detection limit of the ELISA, whereas the ELISA absorbance of PK undigested samples
was approximately one log higher. RML6 and rmPrP22-230 standards were both in the linear
range (Figure 42 e + f).
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Figure 42: PrPSc-ELISA with chronically infected scCAD cells transfected with 30nM Prnp targeting and scrambled
non-target siRNAs incubated for 72 hours. Manual forward transfection a) with subsequent PK digestion and
b) without PK digestion resulted in significantly reduced PrPSc and PrPC levels by Prnp siRNA compared to the
scrambled siRNA control. Robotic reverse transfection c) with subsequent PK digestion and d) without PK digestion
resulted in higher inter-well variability and the difference between Prnp siRNA and scrambled siRNA treated cells
was less distinct than with manual forward transfection. e) The Standard with RML6 brain homogenate was in the
linear range with 0.5 – 0 µg RML6 per mL. f) The rmPrP22-230 standard was in the linear range with 0.6 – 0 µg
protein.
To enhance the transfection efficiency with reverse robotic transfection, I increased the siRNA
concentrations stepwise from 30nM to 40nM (Figure 43). The difference between cells treated
with Prnp siRNA and scrambled siRNA was significant with 37.5 nM siRNA.
I repeated the same experiment and reduced the incubation time from 72 hours to 48 hours in
order to minimize the incubation time of the cells and biological variability. However, the siRNA
efficiency was decreased (Figure 44).
Figure 43: PrPSc-ELISA with chronically infected scCAD cells reversely transfected with the robot with siRNA
concentrations ranging from 30 – 40 nM. Prnp targeting and scrambled non-target siRNAs were incubated for
72 hours. All samples were digested with PK. ELISA absorbance represented PrPSc levels. Robotic reverse
transfection showed significant distinction between Prnp siRNA and scrambled siRNA treated cells at 37.5 nM
siRNA but not with other siRNA concentrations.
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Figure 44: PrPSc-ELISA with chronically infected scCAD cells reversely transfected with the robot with siRNA
concentrations ranging from 30 – 40 nM. Prnp targeting and scrambled non-target siRNAs were incubated for
48 hours. All samples were digested with PK. ELISA absorbance represented PrPSc levels. Robotic reverse
transfection did not show significant distinction between Prnp siRNA and scrambled siRNA treated cells.
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In order to get a higher PrPSc signal, I transfected PrP overexpressing HyCAD cells and chron-
ically infected scHyCAD cells with control siRNAs and performed PrPSc-ELISA upon PK diges-
tion (Figure 45 a + b). CAD5 Prnp-/- cells served as negative control. I transfected the cells
with 37.5nM Prnp siRNA and scrambled siRNA, since this concentration had resulted in the
best knockdown efficiency in previous experiments with scCAD cells. The PrPSc signal was
significantly higher than in PrPSc-ELISA with CAD5 wild type and chronically infected scCAD
cells. I compared manual forward to robotic reverse transfection. Knockdown efficiency was
better and inter-well variability lower in manual forward than robotic reverse transfection. This
led to better SSMD values defined for a strong control for hyCAD and scHyCAD in manual
forward transfection (SSMD = -2.6 good screen quality) than in robotic reverse transfection
(SSMD = -0,9 inferior screen quality). Z’ prime factors, which were a more stringent quality
control for screens were insufficient (Zhang 2007). PK digestion of PrPC was complete. As
well in samples that were not digested with PK the variability was higher and the knockdown
efficiency lower in cells reversely transfected with the robot, which resulted in better SSMD
values for manual forward transfection. (Figure 45 c + d).
To increase the transfection efficiency, I tested control siRNA concentrations from 5 nM to 70
nM and compared manual forward to reverse robotic transfection (Figure 46 + 47). Again, man-
ual forward transfection of scHyCAD resulted in better knockdown efficiency and less variability
than robotic reverse transfection. Manual forward transfection led to efficient knockdown from
5nM to 40nM. siRNA concentrations above 40 nM decreased the cell viability. With robotic
reverse transfection, siRNA concentrations   30nM led to significant knockdown while cell via-
bility was not affected by high siRNA concentrations. Samples without PK digestion served as
additional control for knockdown efficiency and completeness of PK digestion.
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Figure 45: PrPSc-ELISA with PrP overexpressing HyCAD and chronically infected scHyCAD cells showed higher
ELISA signal than CAD5 wt and scCAD. Cells were transfected with 37.5 nM Prnp targeting and scrambled non-
target siRNAs for 72 hours. SSMD screen quality control defined for a strong control was better for hyCAD and
scHyCAD in manual forward transfection (SSMD = -2.6 good screen quality) than robotic reverse transfection
(SSMD = -0,9 inferior screen quality). PK digestion was complete in a) and b). SSMD for for hyCAD and scHyCAD
without PK digestion showed the same picture as with PK digestion and better SSMD values with manual forward
transfection.
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Figure 46: PrPSc ELISAs with PrP overexpressing HyCAD and chronically infected scHyCAD transfected with
siRNAs ranging from 5 to 30nM. I compared manual forward transfection to reverse robotic transfection with and
without PK digestion. Manual forward transfection led to efficient knockdown from 5nM to 30n. With robotic re-
verse transfection, siRNA concentrations below 30nM did not lead to significant knockdown. Samples without PK
digestion served as additional control for knockdown efficiency and completeness of PK digestion.
I attempted to reduce the variability between wells when reversely transfecting the cells with
the robot, by printing siRNAs into Opti-MEM to avoid evaporation after printing and potential
RNA degradation (Figure 48 c - f). However, transfection efficiency was more efficient without
pre-filling Opti-MEM (Figure 48 a + b). Direct seeding of cells onto freshly printed siRNA plus
Lipofectamine resulted in better knockdown than freezing of the siRNAs prior to cell seeding
(Figure 48 c - f). Knockdown efficiency was better with 37.5 nM siRNA than with 30nM in
robotic reverse transfection. After these optimizations the strictly standardized mean difference
(SSMD) for robotic reverse transfection was still poor and z’ factors insufficient.
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Figure 47: PrPSc ELISAs with PrP overexpressing HyCAD and chronically infected scHyCAD transfected with
siRNAs ranging from 40 to 70nM. I compared manual forward transfection to reverse robotic transfection with and
without PK digestion. Manual forward transfection led to efficient knockdown from with 40nM. siRNA concentrations
above 40 nM decreased the cell viability. With robotic reverse transfection, siRNA concentrations higher than 30nM
led to significant knockdown while cell viability was not affected by high siRNA concentrations. Samples without PK
digestion served as additional control for knockdown efficiency and completeness of PK digestion.
To investigate whether the transfection efficiency was reduced by robotic transfection, I com-
pared manual reverse transfection with 30nM or 40nM siRNA to robotic reverse transfection
(Figure 49). Robotic reverse transfection resulted in more efficient knockdown than manual
reverse transfection, and manual forward transfection in the best knockdown efficiency and
lowest variability.
Figure 48: PrPSc ELISA with PrP overexpressing HyCAD and chronically infected scHyCAD. a) manual forward
transfection with 37.5 nM siRNA resulted in the same SSMD value as with b) 30nM siRNA and was in the excellent
range. Robotic reverse transfection with pre-filling Opti-MEM to plates before siRNA printing and direct cell seeding
upon siRNA printing resulted in better siRNA knockdown and SSMD values with c) 37.5 nM siRNA (SSMD = -2.3
good) than with d) 30nM siRNA (SSMD = -1.8 inferior). Robotic reverse transfection with pre-filling Opti-MEM to
plates before siRNA printing and freezing before cell seeding resulted in high inter-well variability, low knockdown
efficiency and insufficient SSMD levels with e) 37.5 nM siRNA and f) 30nM siRNA.
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Thus, I established forward transfection for the PrPSc-ELISA screen on the robotic platform
(Figure 50). I printed the siRNAs into an intermediate plate, added Lipofectamine R  RNAiMAX
Reagent and transferred the siRNA-Lipofectamine complexes to plates with previously seeded
scHyCAD cells using the robotic Perkin Elmer platform.
Figure 49: Comparison of manual vs. robotic reverse transfection to manual forward transfection with 30 and 40
nM siRNA. Manual reverse transfection with 30nM siRNA resulted in higher inter-well variability than robotic reverse
transfection. The transfection efficiency was improved with 40nM in manual reverse transfection, but not in robotic
reverse transfection. Manual forward transfection with 30nM siRNA resulted in the best knockdown efficiency and
lowest variability. With 40nM the viability the cell viability was reduced, reflected by lower ELISA absorbance in
non-target controls.
The test screen with control siRNAs resulted in a good SSMD value with distinct separation of
non-target and Prnp siRNA treated controls (Figure 51).
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Figure 50: PrPSc-ELISA with forward transfection on the robotic platforms. 2800 chronically infected scHyCAD
cells were seeded per well into 384-well plates. siRNAs were printed into an intermediate plate, Lipofectamine R 
RNAiMAX reagent was added and the siRNA-Lipofectamine complexes transferred to the cells. PK-digested, de-
natured and neutralized samples were transferred to ELISA plates and PrPSc-ELISA was performed.
I performed a PrPSc-ELISA screen with chronically infected scHyCAD transfected with robotic
forward transfection with the murine non-druggable chaperone siRNA library. Before measur-
ing the RT-Glo luminescence signal for cell viability with the Envision reader, I acclimatized the
plates for one hour to room temperature. QC showed that the RT-Glo luminescence signal was
homogeneous with some irregularities in plate four (Figure 52 a). Cell viability passed the QC,
because non-target and Prnp siRNA treated controls were comparable (Figure 52 b). Viability
was significantly decreased in cells transfected with six siRNAs (Figure 52 c).
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Figure 51: PrPSc test screen with robotic forward transfection of Prnp targeting and scrambled siRNAs resulted
in good SSMD value (-2.14) defined for a strong control. a) In the scatter plot each dot represented one well of
cells treated with control siRNAs. b) The same data depicted as histogram with the customized software including
un-transfected cells (samples). Samples overlap with the non-target control.
The QC of the ELISA absorbance signal showed oversaturation (Figure 53 a). Thus, the
signal of all controls and samples shared the same high values at the upper detection limit
and no distinction between controls was possible (Figure 53 b). The SSMD values were in the
unacceptable range.
Figure 52: RT-Glo levels representing cell viability were visualized for six plates as heatmaps. Low RT-Glo levels
around 200’000 were depicted in blue, medium RT-Glo levels around 400’000 were shown in dark orange, and high
RT-Glo levels above 600’000 were shown in bright orange. RT-Glo luminescence signal was homogeneous with
some irregularities in plate four b) Cell viability of scHyCAD cells treated with scrambled siRNA and siRNA targeting
Prnp was comparable. c) Six siRNAs significantly reduced the cell viability of scHyCAD, compared individually to
the mean cell viability of all non-target controls (one dot = mean non-target control viability of one plate). For each
siRNA technical duplicates were depicted.
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6.1.4 Hit validation murine PrPC and PrPSc screens
I planned to validate chaperone hits with two siRNAs per chaperone, differing in the targeting
locus from the siRNAs used in the screen (Figure 54). After assessing PrP levels upon treat-
ment with hit targeting siRNAs by Western blotting, I purposed to test the knockdown efficiency
of hit targeting siRNAs and their effect on PrP levels by quantitative real-time PCR (qRT-PCR).
Subsequently I planned to confirm chaperone hits in a different cell line and to apply the hit
validation strategy to following screens.
Figure 53: a) ELISA absorbance levels representing PrPSc levels were visualized for six plates as heatmaps.
Because the signal was oversaturated, all samples high PrPSc levels around 2, depicted in bright orange. b) ELISA
absorbance quality controls from the PrPSc screen showed no difference between hyCAD control (blue), Prnp
targeting siRNA control (green), non-target siRNA control (orange) and samples (violet) because the signal was
oversaturated.
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I selected five hits (Hspa5, Psmc5, Calr, Canx and Hspa4) from the first PrPC SKD screen with
druggable chaperones, to establish hit validation. For each hit I ordered two siRNAs, differing
in the targeting locus from the siRNAs used in the screen. I transfected CAD5 wt cells with the
hit targeting siRNAs and extracted protein and RNA. CAD5 wt cells transfected with scrambled
and Prnp targeting siRNAs served as controls. I designed primers against the chaperone
hits and tested their quality with amplification and standard curves by qRT-PCR (Figure 55). I
designed new primer pairs for such that did not pass quality control.
Figure 54: Hit validation strategy.
In order to cope with variability caused by different siRNA treatment of CAD5 wt cells, I tested
8 different housekeeping genes (B2m, Eif2a, Gapd, Hmbs, Hprt, Ppib, Tbp, Utp6c). I included
B2m, Gapdh, Hprt and Ppib as stable housekeeping geenes, which I used in every experiment
as controls. I normalized all samples to Hprt, the most robust housekeeping gene. I established
the qRT-PCR protocol on a LabCyte acoustic dispensing robot for 384 well plate format and
compared it to the results of manually pipetted RT-PCR in 96 well plates (Figure 56).
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Figure 55: Testing primers against chaperone hit Hspa5. The same amount of primers was added to five 1:10 dilu-
tions of cDNA from untreated CAD5 wt. Starting concentration was 100 ng cDNA. a) The amplification blot showed
congruent amplification of technical duplicates in all cDNA concentrations despite 0.01 ng, indicating sample cDNA
with concentrations until 0.1ng could be used. The negative control with cDNA from untreated CAD5 wt generated
without reverse Transcriptase was not amplified during qRT-PCR. b) The standard curve with slope -3.36 showed
that the cDNA amount actually increased 10-fold with each cDNA dilution. R2 was 0.998 (threshold 0.95), thus the
primer pair passed quality control.
Since the results were comparable, I continued with more efficient dispensing with the acoustic
dispenser (Figure 57 a + b). I performed qRT-PCR with cDNA from CAD5 wt cells treated
with 10 different siRNAs targeting chaperone hits. Untransfected CAD5 wt along with CAD5
wt transfected with Prnp targeting and scrambled siRNA served as controls. The average of
three biological replicates and three technical replicates was depicted in each square of the
heatmaps. All siRNAs despite first siRNA targeting Calreticulin and Hspa5 did lead to efficient
reduction of mRNA. Prnp mRNA was reduced upon transfection with siRNAs targeting Prnp,
Calnexin, Hspa4 and Hspa5.
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Figure 56: Comparison of a) manual pipetting in 96 well format to b) robotic dispensing in 384 well format with
primers against the housekeeping genes B2m, Gapdh, Hprt, Ppib. B2m and Gapdh showed comparable absolute
cDNA quantity as in 96 well format.
Figure 57: Absolute starting quantity (ng cDNA) of CAD5 wt samples transfected with control- and hit chaperone
targeting siRNAs normalized to Hprt. The average of three biological replicates from different passages of CAD5 wt
and three technical replicates was depicted in each square. High cDNA quantity was depicted in red, low quantity
in dark blue. a) All primers were included in the figure. b) To render the figure more clearly, only primers against
chaperone hits and Prnp were depicted. Squares highlighted in yellow showed knockdown efficiency siRNAs
targeting hit chaperones. All siRNAs despite first siRNA targeting Calreticulin (Calr 1) and Hspa5 (Hspa5 1) did
lead to efficient reduction of mRNA. Squares highlighted in orange showed significant downregulation of Prnp. Prnp
mRNA was reduced upon transfection with siRNAs targeting Prnp, Calnexin, Hspa4 and Hspa5.
80
Figure 57: (Description on the previous page.)
81
When converting the same qRT-PCR results into a bar graph and comparing the mRNA level
to the protein level in a Western blot, I could confirm reduction of PrP levels upon treatment
with chaperone targeting siRNAs Prnp, Calr 1, Canx 1 and Hspa5 2.
Figure 58: Comparison of the protein level in a Western blot to the mRNA level from qRT-PCR. I could confirm
reduction of PrP levels upon treatment with chaperone targeting siRNAs Prnp, Calr-1, Canx-1 and Hspa5-2.
To establish hit validation for PrPSc screens, I transfected five different cell lines (CAD5 wt,
chronically infected scCAD, PrP overexpressing hyCAD, chronically infected scHyCAD and
CAD5 Prnp-/-), with Prnp targeting siRNA and performed PK-Westerns (Figure 59 a). In all
five cell lines PrPC or PrPSc levels respectively were clearly reduced upon transfection with
Prnp targeting siRNA. To validate the chaperone hit Hspa5, I transfected the five cell lines with
Prnp and Hspa5 targeting siRNAs. PK-Western showed, that both siRNAs led to reduction of
PrPC in CAD5 and hyCAD cells. PrPSc levels in scCAD and scHyCAD were clearly reduced
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as well (Figure 59 b + c). To confirm chaperone hits in a different cell line than CAD5, I tested
whether murine N2A PK1 cells were susceptible to murine RML6 prions by acute and chronical
infection (Mahal, Baker et al. 2007). I chose N2A PK1 for their neuronal phenotype and for
their high susceptibility to RML6 prions. PK-Western showed PrPSc bands in both, acutely and
chronically infected N2A PK1 cells (Figure 60 a + b). Acute infection of N2A PK1 resulted in a
less strong PrPSc band than acute infection of hyCAD cells, but much stronger than in CAD5
Prnp-/- cells. N2P PK1 cells chronically inoculated with RML6 showed a PrPSc band, whereas
in untreated and NBH treated cells all PrPC was completely digested. These results indicated
that N2A PK1 cells were susceptible to RML6 prions. However, the knockdown efficiency in
chronically infected N2A PK1 transfected with Prnp and non-target siRNA (5 – 70 nM siRNA)
was very low and the cell viability decreased substantially with siRNA concentrations higher
than 30nM (Figure 61).
Figure 59: PK-Western with five different cell lines transfected with Prnp targeting siRNA. RML6 containing brain
homogenate, which served as positive control, exhibited the typical diagnostic shift towards a smaller PK-resistant
core with un-, mono- and di-glycosylated PrPSc (first two lanes). PrPC from uninfected CAD5 cells, was completely
digested and the CAD5 Prnp-/- control showed no PrP. PrPC and PrPSc levels respectively were reduced in all five
cell lines upon transfection with Prnp targeting siRNA. b) PK-Western with CAD5 wt and scCAD transfected with
Prnp and Hspa5 targeting siRNA. PrPC from uninfected CAD5 cells, was completely digested. PrPC and PrPSc
levels in CAD5 wt and scCAD were reduced upon transfection with the two siRNAs. c) ) PK-Western with hyCAD5
and scHyCAD transfected with Prnp and Hspa5 targeting siRNA. As well in hyCAD and scHyCAD cells the PrPC
and PrPSc levels were clearly reduced upon transfection with the Prnp and Hspa5 targeting siRNAs.
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I then tested whether murine myoblastoma CH3H/10T1/2 were susceptible to RML6. Myoblas-
toma cells were potentially interesting, because prion replication of murine Rocky Mountain
Laboratory prion strain had been observed in muscle cells (Bosque and Prusiner 2000). I
acutely and chronically infected CH3H/10T1/2 with RML6. Prnp knockout clone #C5, which
I had generated by CRISPR-Cas9, served as negative control. Western blots of Proteinase
K-digested samples showed a PrPSc band in acute infection, that was weaker than the one in
the Prnp-/- control and no PrPSc band chronical infection (Figure 62 a + b).
Figure 60: PK-Western of a) acute infection of N2A PK1, hyCAD and CAD5 Prnp-/- cells with 0.3 µg/mL RML6.
RML6 containing brain homogenate exhibited the typical diagnostic shift (first two lanes). PrPSc band in RML6
infected hyCAD cells was stronger than in N2A-PK1 cells. Much less residual inoculum in CAD5 Prnp-/- than in
RML6 infected N2A-PK1. b) Chronical infection of N2A PK1 showed a PrPSc band, whereas in untreated and NBH
treated cells all PrPC was completely digested.
Figure 61: PrPSc ELISA with N2A PK1 cells chronically infected with RML6 and manually transfected with Prnp
targeting and scrambled siRNAs (5nM - 70nM) or untransfected (UT). In samples digested with PK, the ELISA
absorbance signal was at the lower detection limit and no significant difference between cells transfected with Prnp
targeting and scrambled siRNAs was evident. PK undigested samples exhibited an ELISA signal one log higher
than PK digested samples. The transfection efficiency was too low to lead to a significant difference between cells
transfected with Prnp targeting and scrambled siRNAs. With siRNA concentrations higher than 30 nM the cell
viability was decreased, indicated by reduced PrP levels in the non-target control.
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Figure 62: a) 10T1/2 acutely infected with 0.3 µg RML6 /mL for 96 hrs. The PrPSc band in acute infection was
weaker than the one in the Prnp-/- control. b) PK-Western with chronically infected 10T1/2 and 10T1/2 Prnp-/- with
0.1 µg/mL RML6 did not show a PrPSc band in both cell lines.
6.2 Chaperone siRNA screens in human cells
6.2.1 Generating human murinized cells for siRNA screening
The human neuroblastoma SH-SY5Y cell line was well characterized and previously used for
investigating neuronal death and alterations in gene expression profile upon prion infection
and were permissive to prion replication when infected with brain homogenate from a sporadic
CJD patient (Ladogana, Liu et al. 1995, Dupiereux, Zorzi et al. 2006, Martinez and Pascual
2007). Based on this, the SH-SY5Y cell line was chosen as model system for the human
chaperone screen. To address prerequisite 1), I had generated PRNP-knockout mutants in the
SH-SY5Y cell line by means of CRISPR-Cas9 during my masters. I had double-transfected
the cells with an MLM3636-based sgRNA plasmid and an expression plasmid simultaneously
expressing Cas9 and EGFP. After selection of clones by single cell fluorescence-activated cell
sorting (FACS), I had expanded the clones in 96 well plates and screened total 350 clones for
PrP levels, which finally resulted in five knockout (PRNP-/-) clones, which I had confirmed by
sequence analysis, real time PCR and FACS binding experiments (V. 2015). I further character-
ized these five knockout clones by enzyme-linked immunosorbent assay (ELISA). All knockout
clones showed clear ablation of PrP, when compared to CAD5 Prnp-/- cell lysate, whereas PrP
in SH-SY5Y wild type was clearly present (Figure 63 a). In order to test the sensitivity of the
ELISA, I spiked SH-SY5Y knockout clones #C75 and #C126 and CAD5 Prnp-/- with SH-SY5Y
wt protein (Figure 63 b). At 1:64 dilution, the wild-type samples were diluted to the sensitivity
limit of the ELISA (100 pg) and showed the same absolute PrPC levels as un-spiked knock out
clones. Absolute PrPC levels of SH-SY5Y wild type were clearly discriminable from the knock-
out clones. Absolute PrP values were interpolated from the linear range of the calibration curve
with rhPrP22-231.
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Figure 63: a) Using sandwich ELISA, I compared the absolute PrPC levels of the five SH-SY5Y PRNP -/- clones to
SH-SY5Y wild type and murine CAD5 Prnp -/- clones. All knockout clones showed clear ablation of PrP and were
not distinguishable from the blank (what is the blank, “i.e. plain medium” etc.). Sample PrPC concentrations were
interpolated from the linear range of the calibration curve with rhPrP22-231. Each sample was compared to the
positive control using an unpaired two tailed t test. b) Sandwich ELISA with SH-SY5Y knockout clones #C75 and
#C126 and CAD5 Prnp-/- with SH-SY5Y wt protein. At 1:64 dilution, the wild-type sampC75 and #C75 and #C126
and CAD5 Prnp-/- with SH-SY5Y wt protein. At 1:64 dilution, the wild-type sampC126 and CAD5 Prnp-/- spiked
with SH-SY5Y wt lysate in 1:2 dilutions. At 1:64 dilution, the wild type samples were diluted to the sensitivity limit of
the ELISA (100 pg) and showed the same absolute PrPC levels as the un-spiked knock out clones. PrP knockout
clones were compared with one-way ANOVA and Bonferroni correction to SH-SY5Y wild type and showed very
clear distinction from absolute PrPC levels of SH-SY5Y wild type.
I confirmed depletion of PrP in the five SH-SY5Y PRNP-/- clones as well by immunoprecipita-
tion (IP) with anti PrP antibody POM1 and subsequent western (Figure 64).
Figure 64:
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Figure 64: Immunoprecipitation with 2000 µg of total protein and western blot with five SH-SY5Y PRNP-/- clones,
SH-SY5Y wt, HEK293 cells and a HEK PRNP-/- clone. Immunoprecipitation of SH-SY5Y wt with IgG did not
pull down any PrP, which showed that immunoprecipitation with POM1 was specific for PrP. Blocking POM1 with
recombinant human PrP22-231, did work, the band at 23-25 kDa corresponded to the molecular weight of rhPrP22-
231. PrP levels of SH-SY5Y wt were much lower than in HEK wt. No PrP was present in all knockout clones. a)
IP-Western performed with biotinylated POM2 as 1  antibody and Avidin-HRP. b) IP-Western performed with XN
as 1  antibody and Goat anti rabbit IgG as 2  antibody.
Even when performing immunoprecipitation with 2000 µg of total protein from SH-SY5Y lysate,
the PrP signal in western was very weak. This could be explained by weak expression of PrP
under the control of the PRNP promoter. If I would have murinized the cells by targeted knock-
in of the open reading frame of murine Prnp with CRISPR-Cas9, murine PrP expression levels
could have been low, as well. Therefore, I decided to generate murinized SH-SY5Y by stable
transfection of PRNP -/- clone #C114 with a pcDNA3 plasmid harboring the coding sequence
of murine Prnp and subsequent clonal isolation by limited dilution. Sandwich ELISA showed
that multiple, random integration of murine Prnp into the human genome driven by the strong
(Cytomegalovirus) CMV promoter led to significantly higher expression of murine PrP in six
isolated clones (#M2, #M4, #M5, #M6, #M7, #M9, #M12), than in SH-SY5Y wild type and
PRNP -/- #C114 clone (Figure 65).
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Figure 65: Sandwich ELISA with samples diluted 1:2 from a starting concentration of 16 µg/mL. a) relative PrP
values of murinized SH-SY5Y clones were significantly higher than in wild type (wt, red) and SH-SY5Y PRNP-/-
(KO, black) cells. #M6 showed the highest PrP expression (brightest grey scale), #M4 the lowest (darkest grey
scale). b) Absolute PrP values were interpolated from the linear range of the calibration curve with rhPrP23-231.
Murinized SH-SY5Y clones were, individually compared to SH-SY5Y wild type. *** p < 0.001, unpaired, two-tailed
T-test.
I tested the susceptibility of murinized SH-SY5Y cell lines to murine prions by acute infection.
Since sibling clones of the same cell line can show very different relative susceptibilities to prion
strains, I tested a pool of seven murinized SH-SY5Y clones (mSY5Y) in addition to single clone
#M4 (Bosque and Prusiner 2000). To check strain specific susceptibility, I acutely infected
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mSY5Y, as well as #M4 clone and SH-SY5Y PRNP-/- cells with eight different prion strains
(RML6, 22F, 22L, 236K, 87A, 79A, ME7, mNS) and according non-infectious brain homogenate
(Figure 66).
Figure 66: Overview of eight different prion strains and according non-infectious brain homogenate used for acute
infection of murinized SH-SY5Y cells and PRNP-/- cells.
Western blots of proteinase K-digested cells acutely infected with 79A, ME7 and mNS strains
showed PK resistant PrP bands stronger than the one in the SH-SY5Y PRNP-/- control, which
served as negative control and does not replicate prions (Figure 67 g, h, i). The remained prion
strains either showed no PK resistant bands in murinized cells or a strong band in SH-SY5Y
PRNP-/- controls, pointing towards residual inoculum (Figure 67).
Figure 67: Acute infection of mSY5Y, single clone #M4 and SH-SY5Y PRNP-/- cells with eight different prion
strains (RML6, 22F, 22L, 236K, 87A, 79A, ME7, mNS) and according non-infectious brain homogenate. The di-
gested infectious brain homogenate shows the typical shift towards a smaller PK-resistant core. a) Acute infection
of #M4 with RML6 showed a PrPSc band in infected #M4 and a stronger PrPSc band in SH-SY5Y PRNP-/- cells. b)
Acute infection of mSY5Y with RML6 showed no PK resistant bands. c) Acute infection of #M4 and mSY5Y pool
with 22F showed incomplete digestion of PrPC in NBH treated M4 and no PK resistant bands. d) Acute infection of
#M4 and mSY5Y pool with 22L showed, that PrPC digestion of NBH treated #M4 was incomplete. The PrPSc band
in SH-SY5Y PRNP-/- cells was stronger than in #M4 and mSY5Y. e) Acute infection of #M4 and mSY5Y pool with
263K hamster prions did not show any band in PK-Western despite in untreated, PK-undigested #M4 and mSY5Y.
f) PK-Western with #M4 and mSY5Y pool acutely infected with 87A showed strong PrPSc bands in all infected cells.
g) Acute infection of #M4 and mSY5Y pool with 79A showed stronger bands in infected #M4 and mSY5y than in
PRNP-/- cells. PrPC was not completely digested in NBH treated mSY5Y. h) Acute infection with ME7 showed a
PrPSc band in #M4, no PrPSc in mSY5Y and very little residual inoculum in PRNP-/- cells. i) Acute infection with
mNS showed a PrPSc band in infected #M4 weaker than the residual inoculum in PRNP-/- cells and an PrPSc band
in infected mSY5Y cells stronger than the residual inoculum in PRNP-/- cells. PrPC was not completely digested in
NBH treated M4.
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Figure 67: (Description on the previous page.)
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Because RML6 was commonly used in our lab and my colleague Daniel Pease had performed
a PrPC screen with #M4 cells and was opting for a PrPSc screen too, I tested whether #M4
cells could be infected RML6 prions by chronical infection. The PK-Western blot did not show
any PK-resistant murine PrP aggregates (Figure 68).
Figure 68: Chronical infection of #M4 with RML6. Samples were digested with 2, 5 and 10 µg PK /mL. The blot
was highly overexposed, so the typical diagnostic shift in the molecular weight of PrP was not visible in the positive
control with brain homogenate of terminally sick mice infected with RML6, digested with PK. PK digestion with 2 µg
PK/mL resulted in residual PrPC. 5 µg PK/mL were necessary to completely digest PrPC. The Western blot did not
show a PrPSc band in #M4 cells inoculated with RML6.
To test potential presence of PK-sensitive material in #M4, I ultracentrifuged the samples on a
10% - 60% sucrose gradient and collected fractions for Western blotting. On western blots, I
did not find any PK-sensitive murine PrP aggregates in RML6 infected #M4 cells (Figure 69).
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Figure 69: Western blots with fractions from gradient centrifugation. The density of the sucrose gradient was
indicated by the scale with lowest density (10% sucrose) on the left, and highest density (60% sucrose) on the
right side. a) The Western blot with non-infectious brain homogenate (NBH) fractions showed PrP in low density
fractions and no PrP in high density fractions. b) The blot with RML6 brain homogenate did show PrP in low and
high density fractions. c) The Western with untreated #M4 cell lysate showed PrP in low density fractions and
in the highest density fraction. d) High density fractions of #M4 chronically infected with RML6 did not show any
PK-sensitive PrPC aggregates but clear bands in low density fractions.
Immunohistochemistry of #M4 revealed physiological membrane-bound expression of murine
PrP and no stalling in the ER, which could have prevented prion replication (Figure 70) (Cardi-
nale, Filesi et al. 2005).
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Figure 70: Confocal microscopy images of immunostaining of PrP with POM1 antibody in #M4 showed physiolog-
ical expression of PrP at the membrane. SH-SY5Y PRNP-/- cells did not show any PrP. Scale bar 10 µm.
Sequencing of #M4 showed an unaltered wild-type Prnp sequence which led me to exclude
any alterations of the murine PrPC that would hinder RML6 replication. When I chronically
infected the mSY5Y pool and single clone #M4 with the three strains (79A, ME7 and mNS),
that had shown PK-resistant bands in PK-Western upon acute infection, no PrPSc band was
visible in PK-Westerns siehe oben (Figure 71).
Figure 71: PK-Westerns with chronical infection of mSY5Y pool and #M4. There was no residual inoculum in al
SH-SY5Y PRNP-/- controls treated with infectious brain homogenate and digested with PK. a) Chronical infection
of #M4 with 79A did not show a PK resistant band, but some residual PrPC in the NBH treated control. Chronical
infection of mSY5Y with 79A b) and mNS d) did not show PK resistant bands. c) Neither did chronical infection of
#M4 with ME7.
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Figure 71: (Description on the previous page.)
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In a different approach, I stably transfected the human glioblastoma cell line U-251MG with
a pcDNA3 plasmid encoding the open reading frame of murine Prnp. I assumed that murine
PrPC overexpression outranged endogenous human PrPC expression and might render the
cells susceptible to murine prions, if they expressed the required cellular machineries for prion
replication. I acutely infected mixed clones of U-251MG overexpressing murine PrP and un-
transfected cells as negative control with murine RML6 prions. PK-Western with mouse spe-
cific POM19 antibody showed that U-251MG transfected with Prnp actually expressed much
more PrPC in comparison to untransfected UMG cells (Figure 72 a). POM19 slightly bound hu-
man PrP. Untransfected U-251MG cells had a stronger PrPSc band, which could be explained
by residual murine RML6 inoculum attached to the cells. PK-Western with human PrP spe-
cific 3F4 antibody showed weak bands in uninfected U-251MG cells, and no human PrPSc in
infected cells (Figure 72 b). Thus, U-251MG did neither replicate RML6 prions, nor human
prions.
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Figure 72: Acute infection of human U-251MG overexpressing murine PrP and untransfected cells as negative
control with murine RML6 prions. a) PK-Western with mouse specific POM19 antibody showed higher PrP levels
in U-251MG transfected with Prnp in comparison to un-transfected UMG cells. POM19 slightly bound human PrP.
Untransfected U-251MG cells had a stronger PrPSc band than PrP overexpressing cells. b) PK-Western with human
PrP specific 3F4 antibody showed weak bands in uninfected U-251MG cells, and no human PrPSc in infected cells.
99
6.2.2 Human PrPC screen
Colleagues from the lab did perform a genome wide human PrPC screen with U-251MG cells
transfected with an arrayed druggable silencer select siRNA library purchased from Ther-
moFisher. The library consisted of 64752 siRNAs targeting 21584 transcripts. Each gene
transcript was targeted by three siRNAs. siRNAs targeting the same transcript were pooled
from 186 source plates to 62 low density volume plates (1536 wells). Three pooled Prnp
siRNAs and the same scrambled non-target siRNAs as in the murine screen were used as
controls. The total screen comprised n = 166 384-well plates. The final siRNA concentra-
tion was 5 nmol. Upon reverse transfection, the RT-Glo luminescence and FRET signal were
measured, after adding Europium-POM2 and APC-POM1.
6.3 Comparison of murine and human siRNA screens
For the murine PrPC screen I used CAD5 cells, which are prion-susceptible cells, derived from
neuronal Cath.a-differentiated (CAD) cells (Qi, Wang et al. 1997). The human glioblastoma
cell line U-251MG was used for the human PrPC screen (Bigner, Bigner et al. 1981). In the two
murine PrPC screens, I screened two different libraries, targeting different chaperone genes.
The same genes that were screened in the two murine PrPC screens, where extracted from
the human genome wide PrPC screen (64752 distinct siRNAs targeting 21584 transcripts) and
compared against one another separately.
6.3.1 Comparison 1. murine PrPC screen vs. human PrPC screen
The first arrayed druggable mouse siRNA library provided by Novartis consisted of 376 siRNAs
against 99 transcripts of druggable chaperones, that were expressed in CAD5 cells based on
a CAD5-RNASeq data set (13’752 expressed genes). Each murine gene was represented by
one row in the heatmap (Figure 73 left).
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Figure 73: Comparison of 1. murine PrPC screen vs. human PrPC screen. Results from the first murine PrPC
screen are shown on the left side, results from the human PrPC screen on the right side.
Each gene in the murine screen was separately targeted by up to four different siRNAs in four
different wells, represented by four different columns (siRNA1 - 4). Each siRNA modulated the
PrPC levels of the transfected cells, which resulted in different PrPC levels, represented by Net-
FRET values. Each square in the heatmap showed the mean Net-FRET level of two technical
replicates treated with the same siRNA. The Net-FRET signal of the murine samples ranged
from 120’000 to 60’000 (Table 1). High Net-FRET levels were shown in red, low Net-FRET
levels in blue. The murine genes were ranked according to the descending Net-FRET signal of
the mean of four siRNAs targeting the same gene. The mean Net-FRET signal of all controls
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transfected with Prnp siRNA was 54’510, whereas the mean Net-FRET signal of non-target
siRNA treated controls was 99’833 (Table 1).
Max Net-FRET Min Net-FRET Mean Pos. Mean Neg.
Mouse 120’000 60’000 54’510 99’833
Human 6’000 4’200 957 5’401
Table 1: Comparison of 1. murine PrPC screen vs. human PrPC screen
The same genes that were screened in the first murine PrPC screen, where extracted from the
human genome wide PrPC screen. Each gene was represented by one row in the heatmap
(Figure 73 right). In the human PrPC screen, three siRNAs targeting the same gene were
pooled in one well. Technical duplicates of cells transfected with the same siRNA pool were
presented in two different columns (FRET1 and FRET2). Each square in the heatmap repre-
sented the Net-FRET level of a single technical replicate treated with the same siRNA pool.
The Net-FRET signal of the human samples ranged from 6’000 to 4’200 (Table 1). High Net-
FRET levels were shown in red, low Net-FRET levels in blue. The human genes were ranked
according to the descending mean Net-FRET signal of the technical duplicates targeted by the
same pool of siRNAs against the same gene. The mean Net-FRET signal of all human con-
trols transfected with PRNP siRNA was 957, whereas the mean Net-FRET signal of non-target
siRNA treated controls was 5’401 (Table 1). Murine and human genes ranked according to de-
scending Net-FRET levels as described above, were correlated by name (Figure 73 middle).
The connecting lines showed the change in the rank of each gene. I compared the rank num-
bers of the first murine PrPC screen and the human PrPC screen and contrasted them to the
chaperones obtained in the first murine PrPC screen based on the best gaussian processed
normalized sample signal versus non-target comparison at a threshold p = 0.001 (Figure 75 a).
Genes leading to downregulation in the murine PrPC screen were written in blue. Two chap-
erone genes leading to downregulation of PrPC were targeted by four siRNAs (yellow), seven
genes were targeted by three siRNAs (dark orange), and 12 genes by two siRNAs (bright or-
ange). Six genes that differed maximally 15 ranks from each other in the murine and human
PrPC screens were marked in bright green and depicted in a Venn diagram (Figure 75 b). Five
genes that differed maximally 30 ranks from each other in the murine and human PrPC screens
were marked in dark green.
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6.3.2 Comparison 2. murine PrPC screen vs. human PrPC screen
The second library consisted of 560 siRNAs against 140 non-druggable chaperone transcripts,
including transcripts that were not expressed in CAD5 cells. In this arrayed mouse siRNA
library purchased from ThermoFisher, one gene was targeted by 4 different siRNAs. Each
gene was represented by one row in the heatmap (Figure 74 left). The murine and human
genes and their Net-FRET levels were depicted, ranked and correlated the same way as in the
comparison of the 1. murine PrPC screen vs. human PrPC screen.
Figure 74: Comparison of 2. murine PrPC screen vs. human PrPC screen. Results from the second murine PrPC
screen are shown on the left side, results from the human PrPC screen on the right side.
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The Net-FRET signal of the murine samples ranged from 30’000 to 10’000 (Table 2). The
mean Net-FRET signal of all controls transfected with Prnp siRNA was 6’862, whereas the
mean Net-FRET signal of non-target siRNA treated controls was 14’550 (Table 2). In the
second murine PrPC screen one siRNA targeting Hyou1 led to very high PrP- and Net-FRET
levels. Because of the high signal, the entire heat map of the second murine PrPC seemed to
show reduced PrPC levels in blue. However, most of the Net-FRET levels were around 15’000,
which corresponded to the non-target controls (14’550). Thus, the high Net-FRET signal from
Hyou1 siRNA masked the gradient of PrP expression.
Max Net-FRET Min Net-FRET Mean Pos. Mean Neg.
Mouse 30’000 10’000 6’862 14’550
Human 7’000 4’000 957 5’401
Table 2: Comparison of 2. murine PrPC screen vs. human PrPC screen.
The Net-FRET signal of the human samples ranged from 7’000 to 4’000 (Table 2). The mean
Net-FRET signal of all human controls transfected with PRNP siRNA was 957, whereas the
mean Net-FRET signal of non-target siRNA treated controls was 5’401 (Table tab2). The
connecting lines showed the change in the rank of each gene. I compared the rank numbers
of the second murine PrPC screen and the human PrPC screen and contrasted them to the
chaperones obtained in the second murine PrPC screen based on the best gaussian processed
normalized sample signal versus non-target comparison at a threshold p = 0.001 (Figure 75
c). Genes leading to upregulation in the murine PrPC screen were written in black. Two genes
were targeted by two siRNAs (bright orange) leading to upregulation of PrP. Both genes differed
more than 30 ranks from each other in the murine and human PrPC screens.
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Figure 75: a) Comparison of rank numbers from the first murine PrPC screen and the human PrPC screen con-
trasted to the chaperones ranked as hits in the first murine PrPC screen based on the best gaussian processed
normalized sample signal versus non-target comparison at a threshold p = 0.001. Genes leading to downregu-
lation in the murine PrPC screen were written in blue. Two genes were targeted by four siRNAs (yellow), seven
chaperones were targeted by three siRNAs (dark orange), 12 chaperones by two siRNAs (bright orange) leading
to downregulation of PrP. b) Six genes that differed maximally 15 ranks from each other in the murine and human
PrPC screens were marked in bright green and depicted in a Venn diagram. Five genes that differed maximally 30
ranks from each other in the murine and human PrPC screens were marked in dark green. c) I compared the rank
numbers of the second murine PrPC screen and the human PrPC screen and contrasted them to the chaperones
ranked as hits in the second murine PrPC screen based on the best gaussian processed normalized sample signal
versus non-target comparison at a threshold p = 0.001. Genes leading to upregulation in the murine PrPC screen
were written in black. Two genes were targeted by two siRNAs (bright orange) leading to upregulation of PrP. Both
genes differed more than 30 ranks from each other in the murine and human PrPC screens.
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Figure 75: (Description on the previous page.)
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7 Discussion
7.1 Chaperone siRNA screens in murine cells
7.1.1 Murine PrPC screens
Recent research has connected chaperones to prion disease (Allen, Wegrzyn et al. 2005,
Rikhvanov, Romanova et al. 2007, Park, Eun Kim et al. 2017). However, no comprehensive
study including all mammalian chaperones has been achieved in prion research. In this study
I presented an unbiased and plenary approach to assess which chaperones are involved in
the biosynthesis of PrPC in the murine neuronal cell line CAD5 by siRNA mediated screens
on two robotic platforms. The screens were comprised of two assays measuring cell viability
and PrPC levels. Viability results were used to define thresholds for extreme low or high cell
viability and implemented in the analysis of the PrP levels to select chaperones altering the
PrP metabolism rather than cell viability. My screens validated the role of Hspa5 and Hsf1
in prion protein metabolism and furthermore discovered 21 novel chaperones involved in PrP
metabolism (Park, Eun Kim et al. 2017) (Steele, Hutter et al. 2008).
I completed two murine PrPC screens with two different siRNA libraries targeting druggable and
non-druggable chaperones. Both screens passed quality control and resulted in 26 siRNAs
leading to upregulation of PrP levels and 82 siRNAs leading to substantial downregulation of
PrP levels. I further tested acute and chronical infection of CAD5 cells with RML6 for the
PrPSc screen. I generated the hyCAD cell line, which is highly susceptible to RML6 prions,
tested numerous conditions for PrPSc assays and finally established a PrPSc-ELISA assay with
chronically infected hyCAD cells on automated robotic screening platforms. I established hit
validation by Western blotting and qRT-PCR on the LabCyte acoustic dispensing robot for 384-
well plate format and tested alternative murine cell lines for hit validation. The quality of the
screens was monitored by comprehensive quality control graphs, which allowed me to optimize
the screen conditions and draw conclusions on the results. I could overcome temperature
dependent variability in the cell viability signal apparent in the quality control of the first PrPC
screen by acclimatizing the plates to the temperature in the Envision reader.
The Net-FRET signal in the first murine PrPC screen (Net-FRET range 54’528 - 123’602) was
higher, than in the second murine PrPC screen (Net-FRET range 8’503 - 31’168). A technical
explanation could be that the labelling of POM1 or POM19 antibodies to APC and Europium
was more efficient in the first screen than in the second screen, so that more labelled anti-
body bound PrPC and elicited a signal. A possible biological explanation of the differences in
PrPC levels between the first and second murine screen could be that PrP is expressed in a
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circadian rhythm, which is why the amount of prion protein messenger RNA can change over a
relatively short period (Cagampang, Whatley et al. 1999). I harvested the cells in the morning
and in the afternoon, which might have an effect on overall PrPC expression levels as PrPC
expression underlies a circadian rhythm. My data confirmed the reported low reproducibility
rates of siRNA data originating from different siRNAs targeting the same genes (Marine, Bahl
et al. 2012). The first screen with r2 = 0.424 for raw Net-FRET signal of duplicates was in a
good range, the second screen with r2 = 0.125 for raw Net-FRET signal of duplicates was com-
parable to published results where two different siRNA sets targeting the same genes showed
a correlation coefficient R around 0.2 depending on the screens. Pooling siRNAs increased
replicate correlation substantially (Ramo, Drewek et al. 2014). A genome wide siRNA screen
with pooled siRNAs led to very good correlation coefficient r2 of 0.6 (Papageorgiou, Rapley
et al. 2015). It could be that the correlation between technical replicates in the second PrPC
screen was lower than in the first screen, because different libraries had been used.
I summarized the functions of al chaperone hits from the PrPC screens in two tables (Appendix
82 + 83). Eleven of the chaperones that were downregulated by siRNAs leading to reduced
PrPC levels were parts of the 26S Proteasome. The 26S proteasome consists of a core 20S
proteasome and one or two 19S regulatory particles (Glickman, Rubin et al. 1998). The 20S
proteasome is a barrel-shaped structure composed of ↵- and  -subunits arranged in four rings
(Figure 76).
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Figure 76: Structure of the 26S proteasome. Subunits that were classified as hits in the murine PrPC screen
were marked with stars. Figure was generated using the DAVID Functional Annotation Bioinformatics Microarray
Analysis webtool (Huang et al. 2009)
The 19S regulatory particle consists of 19 canonical subunits which are divided into lid and
base subcomplexes. The 19S subunits bind, deubiquitinate and unfold ubiquitinated proteins,
and translocate them into the 20S proteasome for degradation (Liu and Jacobson 2013). The
lid consists of 10 non-ATPase subunits (Rpn3, Rpn5–9, Rpn11, Rpn12, and Rpn15). Non-
ATPase subunits Rpn7 and Rpn11 led to downregulation of PrP in the siRNA screen. Rpn11
deubiquitinates substrates prior to their degradation. Connection between lid and base are
stabilized by Rpn10. The base contains six distinct ATPase subunits (Rpt1–6) and three non-
ATPase subunits (Rpn1, Rpn2, Rpn13). Rpt1–6 and Rpn1 led to reduced PrPC levels the
siRNA screen (Figure 76). The six ATPase (Rpt1–6) subunits form the molecular motor for the
proteasome (Lander, Estrin et al. 2012, Zhu, Hayat Khan et al. 2014). When 19S ATPase
binds a nucleotide, HbYX motifs dock into the pockets of ↵-subunits of 20S, functioning as
a ’key in a lock’ to open the gate of the 20S proteasome (Figure 77) (Kim and Smith 2014).
Rpn10 and Rpn13 are ubiquitin (Ub) receptors and can recognize polyubiquitinated substrates
(Zhu, Hayat Khan et al. 2014).
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Figure 77: Mechanism of gate opening of 20S proteasome. When 19S ATPase binds a nucleotide, HbYX motifs
dock into the pockets of ↵-subunits of 20S, functioning as a ’key in a lock’. Reprinted from (Kim and Smith 2014).
License number 4376910427517.
The 26S proteasome is involved in the ubiquitin proteasome system (UPS) and acts in cellular
quality control by degrading misfolded, unassembled, or damaged proteins potentially prone to
aggregation (Hershko and Ciechanover 1998). Degradation of proteins via the UPS pathway
involves two steps: conjugation of ubiquitin to a protein and degradation of the tagged protein
by the 26S proteasome (Ciechanover, Orian et al. 2000). Accumulation of ubiquitin conjugates
are found in the terminal stage of prion disease. Ubiquitination is a late event in prion disease
and occurs after the formation of protease-resistant PrPSc (Kang, Brown et al. 2004). However,
the results from the siRNA screen indicate that the 26S proteasome is already involved in the
functioning of PrPC.
The three chaperones Calnexin, Calreticulin and Hspa5, which are associated to the endo-
plasmatic reticulum (ER), reduced PrPC levels in the siRNA screen. Calreticulin and Calnexin
are members of a family of ER chaperones that fold newly synthesized polypeptides. They
assist in the folding and subunit assembly of the majority of Asn-linked glycoproteins that pass
through the endoplasmic reticulum (Leach 2000-2013). Human PrP is glycosylated at Asn181
and Asn197 on helices 2 and 3 and murine PrP has glycosylation sites as Asn180 and Asn196
(Haraguchi, Fisher et al. 1989). Thus, Canx and Calr might be involved in the proper folding of
PrP. The ER chaperone Hspa5 facilitates folding and assembly of nascent polypeptides, pre-
vents their misfolding and aggregation, targets misfolded proteins for proteasome degradation,
and controls the unfolded protein response (UPR). Hspa5 regulates the UPR by reducing ER
stress levels and apoptosis due to an enhancement of the cellular folding capacity. Hspa5 and
PrP interact in the cellular context. Prion replication in cell culture was shown to be related
to the levels of expression of Hspa5. However, a reduction in the expression of this molec-
ular chaperone accelerates prion pathogenesis in vivo (Park, Eun Kim et al. 2017). I could
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show reduction of PrPC and PrPSc in cell culture with four different cell lines upon reduction of
Hspa5 by RNAi (Figure 59 a+b), indicating that Hspa5 might contribute to both, prion protein
biosynthesis and prion replication.
Fkbp8 reduced PrPC levels in the siRNA screen. Fkbp8 encodes a Peptidyl prolyl cis/trans iso-
merase (PPIase), expressed in the cytosol, ER and mitochondria (Gaudet, Michel et al. 2017).
PPIases assist the folding and restructuring of proteins (Schiene-Fischer 2015). FKbp8 is ac-
tivated by binding Calmodulin and calcium and seems to act as a chaperone for anti-apoptotic
Bcl-2. Recombinantly expressed prion protein has been shown to be a target of anti-apoptotic
Bcl-2 (Kurschner and Morgan 1995). In addition, BCL-2 binds and co-aggregates with mis-
folded PrP in the cytosol, but not in other cellular compartments of human neuronal SH-SY5Y
cells (Rambold, Miesbauer et al. 2006). Overexpression of Bcl-2 in GT1 cells is neuroprotec-
tive and prevents apoptosis induced by amyloidogenic peptide PrP106-126 (Ferreiro, Eufrasio
et al. 2007). The exact mechanism by which Bcl-2 counters apoptosis in cells with cytotoxic
PrP is not fully understood, but binding to Fkbp8 might play a role.
Hspb8 reduced PrPC levels in the siRNA screen. Hspb8 encodes heat shock protein 22
(Hsp22), a small heat shock protein (HSP20 family) localized in the cytosol, which translo-
cates to nuclear foci during heat shock and shows temperature-dependent chaperone activity
(Uhlen, Fagerberg et al. 2015, Pundir, Martin et al. 2017). HSPB8 forms a stable complex with
the HSPA8 co-chaperone Bcl-2 associated anti-apoptotic BAG3 (Carra, Sivilotti et al. 2005).
Hspb8 plays a role in various neurodegenerative diseases such as AD, PD and Huntington
(Vicario, Skaper et al. 2014). Mutations in Hspb8 are related to Charcot-Marie-Tooth disease
type 2 and distal hereditary motor neuropathy and myopathy (Nakhro, Park et al. 2013, Bouhy,
Juneja et al. 2018). Overexpression of HSPB8 in immortalized motoneuronal cell line NSC34
significantly decreased the accumulation of dipeptide repeat proteins (DPRs), which are the
product of expansion of a repeated G4C2 hexanucleotide sequence present in the C9ORF72
gene linked to in ALS and Frontotemporal Dementia (FTD). HSPB8 overexpression might be
an approach to decrease DPR-mediated toxicity and maintain motoneuron viability in ALS and
FTD (Cristofani, Crippa et al. 2018). Misfolded and aggregate-prone TDP-43 species are
targeted to autophagic degradation if they are bound to the HSPB8–BAG3–HSP70 complex
(Crippa et al. 2010a; Crippa et al. 2010b). Hspb8 may be as well involved in the neuroprotec-
tive response of Prion disease.
Sgta reduced PrPC levels in the siRNA screen. Sgta encodes a co-chaperone that binds
newly synthesized and misfolded proteins as well as proteins containing hydrophobic patches
in the cytosol and targets them to the ER (Pundir, Martin et al. 2017). Sgta has been shown
111
to reverse BAG6-dependent ubiquitination of mislocalized protein. Bag6 and Sgta monitor
certain newly synthesized proteins during protein maturation and quality control (Leznicki and
High 2012).
Hspa4 reduced PrPC levels in the siRNA screen. Hspa4 encodes heat shock protein family
A (Hsp70) member 4 expressed in the nucleoplasm and the cytosol (Uhlen, Fagerberg et
al. 2015). It is involved in ATP binding, chaperone-mediated protein complex assembly, and
protein import into the mitochondrial outer membrane (Pundir, Martin et al. 2017).
Hsf1 and Chordc1 did lead to upregulation of PrPC in the siRNA screen. Chordc1 is proposed
to act as co-chaperone for HSP90 and involved in stress response (Pundir, Martin et al. 2017).
The transcriptional regulator of the stress response Hsf1 is known to be involved in prion dis-
ease. WhenHSF1 knockout (KO) mice were inoculated with Rocky Mountain Laboratory (RML)
prions they showed a dramatically shortened lifespan, succumbing to disease approximately
20% faster than controls (Steele, Hutter et al. 2008). I compared Hsf1 and Chordc1 to RNASeq
data from C57BL76J mice inoculated with RML6 and non-infectious brain homogenate (NBH).
mRNA levels were assessed at different timepoints. After 12 weeks post inoculation both Hsf1
and Chordc1 showed decreasing mRNA levels in cerebellum and hippocampus (Figure 78).
Thus, I hypothesized that these genes might be involved in prion disease.
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Figure 78: Hsf1 and Chordc1 showed decreasing mRNA levels in cerebellum and hippocampus in C57BL76J mice
inoculated with RML6 after 12 weeks post inoculation. The images were generated with the Neurinox Bioinformatics
Platform.
7.1.2 Murine PrPSc screen
I started to establish the murine PrPSc screen with a FRET assay and CAD5 cells. Because
FRET was not sensitive enough to detect differences between uninfected and RML6 infected
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CAD5 (Figure 33), I established PrPSc-ELISA, that is sensitive enough to distinguish RML6
brain homogenate at a 10 5 dilution from the blank (Figure 34). This dilution corresponded
to the lowest RML6 dose injected into mice in in vivo assays. Acute infection of CAD5 cells
with RML6 and CAD5 Prnp-/- resulted - even with very low inoculum concentrations - in high
amounts of residual inoculum in CAD5 Prnp-/- cells, masking potential prion replication in
CAD5 wild type cells (Figure 35). Thus, I proceeded in establishment of the PrPSc screen
with chronical infection of cells, where residual inoculum was removed by four consecutive
splitting steps (Figure 36). Western blots with chronically infected scCAD cells digested with
PK showed reduced levels of PrPSc when inoculated with lower RML6 concentrations and with
higher passages (Figure 31). It is generally difficult to keep immortalized continuously growing
cells infected with prions. Loss of infectivity over time could be the result of prion replication that
is slower than cell division (Aguzzi, Lakkaraju et al. 2018). In mice, the level of PrPC expression
correlates with the rate of PrPSc formation (Aguzzi and Calella 2009). Overexpression of PrP
in N2A cells with subsequent chronical infection showed higher and more stable production
of PrPSc that seen in scrapie-infected N2A cells (ScN2A) (Nishida, Harris et al. 2000). I
could confirm this finding by chronical infection of PrP overexpressing hyCAD cells with RML6
prions, which showed more PrPSc than chronically infected CAD5 cells in PrPSc -ELISA and
Western blots upon PK digestion (Figure 38). However, another N2A clone overexpressing PrP
N2a/2M11 was shown to be resistant to RML prions, whereas a N2a/Bos2 clone transformed
with the control plasmid, expressing PrP at about the same low level as the original N2A cells
was most susceptible to prion infection (Enari, Flechsig et al. 2001). These results confirm that
single clones derived from the same cell line vary in their susceptibility to prions. The PrPSc
test screen with PrPSc -ELISA showed distinct separation between the control groups and a
good SSMD value (Figure 51). However, the readout in the PrPSc -ELISA screen had been
complicated through oversaturated absorbance due to a new batch of Streptavidin (Figure 53).
The cell viability quality control showed six siRNAs, which led to starkly reduced cell viability
(Figure 52 c). I compiled an overview of the functions of the genes (Aip, Os9, Dnajb6, Nsfl1c,
Dnajb11) targeted by these siRNAs (Appendix 84). Os9 is involved in the quality control of
ER related degradation, which might play a role in prion disease. Dnajb11 serves as a co-
chaperone for Hspa5 (Pundir et al. 2017). When Hspa5 levels were reduced by RNAi in the
first murine PrPC screen, PrPC levels were decreased too. The reduced cell viability may be
caused by synthetic lethality but caution should be exercised to assess false positives caused
by off-target effects. The established hit validation by Western blotting and qRT-PCR on the
LabCyte acoustic dispensing robot for 384-well plate format provided proof-of-concept with
114
five genes how hit validation could be performed in a larger scale. Three of five genes led to
downregulation of PrPC with siRNAs differing in the sequence from the ones used in the PrPC
screen. Knockdown of two genes (Calr, Psmc5), which reduced PrPC levels in the first murine
PrPC screen did not show the same effect in qRT-PCR and Western blots. This could be due
to the different loci that were targeted by the siRNAs used in hit validation. In the majority
of the genes that led to downregulation of PrPC not all four siRNAs targeting this gene led to
downregulation of PrPC in the RNAi screens. When I tested alternative murine cell lines for
hit validation, I could acutely and chronically infect N2A PK1 cells with RML6 prions (Figure
60). However, the signal in PrPSc-ELISA was very low and the transfection efficiency of Prnp
targeting siRNA was low (Figure 61). The murine myoblastoma cell line CH3H/10T1/2 of which
I had generated Prnp-/- clones by CRISPR-Cas9 seemed not to be susceptible to RML6 and
thus not suitable for hit validation (Figure 62). Due to time reasons I had skipped the double
knockdown and triple knockdown screens to assess compensation of functional failure by one
or two co-chaperones.
7.2 Chaperone siRNA screens in human cells
I had murinized the human SH-SY5Y neuroblastoma cell line to perform a human PrPSc screen
with murine prions without elevated biosafety risk that would arise when working with human
prions. I generated this heterologous human cell culture model for prion propagation by knock-
out of PRNP by CRISPR-Cas9 and overexpression of murine Prnp in a PRNP knockout clone.
Due to very low endogenous PrPC levels of SH-SY5Y wild type cells, which was as well re-
ported in literature, conventional western blotting was not sensitive enough to detect a differ-
ence between SH-SY5Y wild type and PRNP-/- clones (Rambold, Miesbauer et al. 2006).
Thus, I had to perform immunoprecipitation with very high amounts of total protein (2000 µg)
and sandwich ELISA to confirm PRNP knockout in SH-SY5Y (Figures 63 and 64). To as-
sess strain specific susceptibility to murine prions, I acutely infected a pool of seven murinized
clones (mSY5Y), as well as single clone #M4 with eight different prion strains and according
non-infectious brain homogenate and performed Western blotting upon PK digestion (Figure
67). SH-SY5Y PRNP-/- cells served as negative control. PK-Western blots showed that acute
infection with 79A, mNS and ME7 strains resulted in prion replication. When I chronically in-
fected the mSY5Y pool and #M4 with these three strains and RML6, no prion replication was
evident (Figures 68 and 71). To detect potential PK-sensitive PrP aggregates I performed gra-
dient centrifugation with #M4 clone chronically infected with RML6 prions and treated with
non-infectious brain homogenate as controls (Figure 69). The brain homogenate controls
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showed the expected aggregation pattern after gradient centrifugation. The uninfected #M4
control showed PK sensitive aggregates in the highest density fraction. A possible explana-
tion is overexpression of PrP in this clone, which favors aggregation due to higher local PrPC
concentrations. Confocal microscopy images upon immunostaining of PrP in the #M4 clone
showed PrP expression at the membrane (Figure 70). Thus, I could exclude trapping of PrP in
the endoplasmatic reticulum, which impairs PrPC maturation and prevents PrPSc accumulation
(Cardinale, 2005). It is known, that not all cells are infected by chronical infection. The first
data obtained by dilution and subcloning of infected N2A cells revealed that only 1% of the cells
were actually infected (Race 1991). This could be due to inhomogeneously infected cultures
and might be a reason why mSY5Y and #M4 did not show prion replication upon chronical
infection with prion strains, that showed prion replication upon acute infection. Maybe SDS-
PAGE analysis of cell lysates treated with proteinase K, followed by PK-Western blot analysis
was not sensitive enough to detect a small number of infected cells. In fact, Bosque et al. have
shown that Western blotting could detect PrPSc when 10% of the cells were infected with pri-
ons, whereas cell blotting was positive with only 1% of the cells infected (Bosque and Prusiner
2000). Maybe prions replicated to some degree, but at such low levels, that again a more sen-
sitive detection method would have been advantageous. Possibly, prion replication was not as
fast as cell division and thus infectivity was lost during the splitting steps of chronical infection
(Aguzzi, Lakkaraju et al. 2018). Hence it could be, that PrPSc was lost during chronical infec-
tion as I had observed in the chronically scCAD cells, but much faster. Another hypothesis why
chronical infection did not show prion replication with strains that previously showed replication
in acute infection is that prion replication entailed a disadvantage in fitness, which led to some
prion resistant cells that overgrew the system (Aguzzi, Lakkaraju et al. 2018). Sequencing
of #M4 did not show any difference from the wild type sequence, which could have caused
misfolding and aggregation. However, sequencing revealed a Methionine at murine amino acid
polymorphism at PrP codon 128. Maybe the polymorphism of the Prnp sequence encoded
by SH-SY5Y was not compatible with the murine strains. In a different approach to generate
murinized human cells, I stably transfected the human glioblastoma cell line U-251MG with a
pcDNA3 plasmid encoding the open reading frame of murine Prnp. I acutely infected mixed
clones of U-251MG overexpressing murine PrP and untransfected cells as negative control
with murine RML6 prions (Figure 72). U-251MG did neither replicate RML6 prions, nor human
prions. Various factors might influence the susceptibility of a cell line to different prion strains:
the level and the type of PrP molecules expressed in cells, different co-factors necessary for
the replication of the agent such as chaperones, specific RNA species, a particular lipid envi-
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ronment, or a particular prion replicating subcellular environment (Aguzzi, Heikenwalder et al.
2007). In addition, general trafficking of PrP in the different lines can play a role in susceptibil-
ity. The endogenous cleavage and degradation pathways of PrP may also be involved. Finally,
post-translational modifications of PrP (e.g. glycosylation) could modulate the conversion (So-
lassol, Crozet et al. 2003, Aguzzi, Heikenwalder et al. 2007, Aguzzi and Calella 2009). The
screen would have only been feasible with chronically infected cells, because residual inocu-
lum in SH-SY5Y cells acutely infected with 79A, mNS and ME7 prions masked potential PrPSc
replication.
7.3 Comparison murine and human siRNA screens
I compared the rank numbers of the first murine PrPC screen and the human PrPC screen
and contrasted them to the chaperones obtained in the first murine PrPC screen based on
the best gaussian processed normalized sample signal versus non-target comparison at a
threshold p = 0.001. With a stringent selection (maximally 15 ranks difference between murine
and human PrPC screens) six genes showed downregulation of PrP. With a less stringent
selection (maximally 30 ranks difference between murine and human PrPC screens) eleven
genes showed downregulation of PrPC. The two chaperones Hsf1 and Chordc1, which led
to upregulation of PrPC differed in more than 30 ranks between the murine and human PrPC
screens and did thus not correlate. The genes that differ in their impact on PrP modulation
might be specific for mice and humans. Differences in the ranking can be explained by the
different cell types that were used. For the murine PrPC screen I used CAD5 cells, which
are prion-susceptible cells, derived from neuronal Cath.a-differentiated (CAD) cells (Qi, Wang
et al. 1997). The human cell line U-251MG was used for the human PrPC screen (Bigner,
Bigner et al. 1981). CAD5 cells are neuroblastoma cells, whereas U-251MG are glioblastoma
cells. The two cell lines differ in the degree of ploidy. Human U-251MG are diploid, CAD5
are polyploid. Thus, the cells might differ in their gene expression pattern. The overall PrP
signal could vary between the murine and human PrPC screens due to different amounts of
PrP expressed by the cells, time of harvesting the cells because PrP expression is circadian or
efficiency of APC and EU coupling. Technically, the screens were performed slightly different.
The murine screen was performed with single siRNAs targeting the same gene in different
wells, which bears the advantage of directly knowing which locus leads to downregulation of
Prnp. The human PrPC screen was performed with three pooled siRNAs, which results in
better replicate correlation and saves time and resources, which is advantageous in a whole
genome screen (Ramo, Drewek et al. 2014). The ranking of the Net-FRET signal was as
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well not the same in the murine and human PrPC screens. The murine genes were ranked
according to the descending Net-FRET signal of the mean of four siRNAs targeting the same
gene. The human genes were ranked according to the descending mean Net-FRET signal of
the technical duplicates targeted by the same pool of siRNAs against the same gene.
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8 Outlook
8.1 Chaperone siRNA screens in murine cells
It would be interesting to perform double knockdown and triple knockdown screens to assess
compensation of functional failure by one or two co-chaperones. For the PrPSc screen I plan to
assess different ELISA substrates to bring the absorbance signal in a sufficiently high, but not
oversaturated range. For proper assessment of PrP levels by Western blots upon transfection
of cells with chaperone targeting siRNAs, at least three biological and technical replicates
should be used. For a proof-of-concept, I had only used one replica per siRNA treatment. The
effect of chaperones on PrP levels could be assessed as well by RNA-seq upon transfection
of CAD5 cells with chaperone targeting siRNAs. RNA-seq data could then be confirmed by
qRT-PCR, that I had established on the acoustic dispenser for 384-well format. RNA-seq is
one method to test off-target effects but other deregulated genes could be indirectly affected
by the siRNAs targeting the chaperone transcripts. If two additional siRNAs differing in the
sequence from the ones used in the screen lead to the same modulation of PrP as observed in
the RNAi screen, off-target effects can be excluded. Another method to confirm specificity and
rule out off-target effects is using CRISPR-Cas9. Further it would be worth to investigate if the
specific chaperones alter the levels of PrPC alone or if they also alter the levels of other proteins
that are associated with neurodegeneration, more specifically: A  and other amyloid inducing
proteins. It would be highly interesting to overexpress chaperones downregulating PrP levels
in cells and assess PrPSc levels later on. N2A PK1 which I had tested as an alternative cell
line for hit validation showed reduced cell viability upon infection with RML6 prions. Toxicity of
the crude brain homogenate could be reduced by pre-treating infectious brain homogenate for
30 min at 80 C followed by sonication. This method had been shown to reduce the toxicity of
infectious brain homogenate on cell cultures (Solassol, Crozet et al. 2003). To increase the
PrPSc signal in infected N2A cells, hit validation could be performed with a PrP overexpressing
N2A cell line such as N2a#58 which showed stable and high PrPSc levels (Nishida, Harris et
al. 2000). Non-carcinogenic cells such as primary neurons or neurons derived from induced
pluripotent stem cells (iPSCs) would provide a more physiological system for hit validation than
cancer cell lines.
8.2 Chaperone siRNA screens in human cells
Since only acute infection of murinized human SH-SY5Y cell lines was successful, a scrapie
screen with these cells would not be feasible because residual inoculum in acute infection
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masked potential PrPSc replication. In order to generate a murinized human cell line, either
subcloning of already infected cells with selection of prion susceptible clones would be an
option. Performing more sensitive PrPSc assays thanWestern blotting upon PK digestion would
be another option. Another possibility could be to increase the time between passages during
chronical infection to allow slow prion replication. Starting with a new cell line would bear
the advantage to select a naturally high PrP expressing cell and match human amino acid
polymorphism 129 and murine polymorphism 128 sites in advance with selected prion strains.
Once a suitable cell line is generated, the PrPC FRET and PrPSc ELISA screens could be
performed with the genome wide siRNA library, that had already been used for the human
PrPC screen with U-251MG cells.
8.3 Comparison murine and human siRNA screens
Once established, it will be highly interesting to compare as well murine and human PrPSc
screens. The comparison would be more meaningful if the screens would be performed in the
same way, performing both murine and human screens with a neuroblastoma cell line and with
a pooled siRNA library. It would be informative to screen different cell lines in both, murine and
human screens and compare these to each other and gain knowledge about the actors of the
prion protein replication machinery.
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9 Material & Methods
9.1 Chemicals
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. All DNA oligonu-
cleotides were synthesized by Microsynth. The protein concentration was determined using
the Pierce BCA Protein Assay Kit (ThermoFisher).
9.2 Cell lines
All cells were grown in T150 flasks, maintained in a cell incubator at 37 C in 95% humidity and
5% CO2 and routinely split 1:3 every 3-4 days.
SH-SY5Y: Originally derived from a metastatic bone tumor biopsy, SH-SY5Y (ATCC R  CRL-
2266TM) cells are a subline of the parental line SK-N-SH (ATCC R  HTB-11TM). SK-N-SH were
subcloned three times; first to SH-SY, then to SH-SY5, and finally to SH-SY5Y. SH-SY5Y were
deposited to the ATCC R  in 1970 by June L. Biedler (Biedler, Helson et al. 1973) (Biedler,
Helson et al. 1973, Biedler, Roffler-Tarlov et al. 1978, Kovalevich and Langford 2013). SH-
SY5Y neuroblastoma cell line was cultured in 50% MEM, 50% F-12 supplemented with 10%
heat-inactivated fetal bovine serum (FBS) (ThermoFisher), 0.5% Glutamax, and 1% penicillin-
streptomycin (all Gibco).
C3H/10T1/2 is a clonal myogenic cell line established and characterized by Reznikoff et al.
(Reznikoff, Brankow et al. 1973). The tissue of origin is unknown because the cell line was
derived from C3H whole mouse embryos (Pinney and Emerson 1989). C3H/10T1/2 were cul-
tured at 37 C in DMEM with the addition of 10% FBS (ThermoFisher), 1% Glutamax, and 1%
penicillin-streptomycin (all Gibco). The cells were a kind gift from the Laboratory of Transla-
tional Nutrition Biology, Institute of Food, Nutrition and Health, ETH Zurich.
The mouse cell line CAD-2A2D5 (CAD5) was derived from Cath.a-differentiated cells and is
highly prion-susceptible (Qi, Wang et al. 1997, Mahal, Baker et al. 2007). The mouse cell
line N2aPK1 is a highly prion susceptible subclone from N2aPD88. N2aPD88 is a less prion
susceptible clone from N2a cells challenged with a 10 6 dilution of RML strain (Klohn, Stoltze
et al. 2003). CAD5 and N2aPK1 cells were cultured at 37 C in Opti-MEM with the addition of
10% FBS (ThermoFisher), 1% Glutamax, and 1% penicillin-streptomycin (OFBS medium, all
Gibco). The human embryonic kidney cell line HEK293 was purchased by ATCC. The HEK293
PRNP-/- clone #F2 was generously provided by Mario Hermann.
The human glioblastoma cell line U-251MG was isolated from an astrocytoma tumor by explant
technique and obtained from ATCC (Bigner, Bigner et al. 1981). The cells were cultivated in
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Opti-MEM with the addition of 10% FBS (ThermoFisher), 1% Glutamax, and 1% penicillin-
streptomycin, and 1% Non-Essential Amino Acids (all Gibco).
9.3 Generation of stable cell lines
The coding sequence of murine Prnp was amplified by PCR. Restriction sites for subsequent
cloning into pcDNA3 (Addgene) were attached. The random sequence of 8 bp at the 5’ end of
the primer was attached to ensure efficient DNA cleavage by the restriction enzyme.
5’ AGG TAC CA TCTAGA GGATCC AGGCGACGTGGAAGAAAA 3’
Random XbaI BamHI Primer
5’ AAG TCC TA CCATGG GAATTC TTGTAATCCAGAGGTTGATTATCG 3’
Random NcoI EcoRI Primer
The PCR product was cloned into pcDNA3 (Addgene) at the BamHI and EcoRI restriction sites
(pcDNA3-Prnp). Cells were stably transfected with pcDNA3-Prnp and Lipofectamine 2000
(ThermoFisher). Cellular clones were obtained by limited dilution and selection with G418
(Gibco).
9.4 siRNA libraries and control siRNAs
For the murine chaperone screens an arrayed murine siRNA library consisting of 376 siR-
NAs targeting 99 druggable chaperone transcripts was provided by the Novartis Institute for
Biomedical Research. Each transcript was targeted by two up to five siRNAs. A second
murine siRNA library containing 560 siRNAs targeting 140 non-druggable chaperone tran-
scripts was purchased from ThermoFisher. Each transcript was targeted four siRNAs. The
sequence of the control Prnp-siRNA (from ThermoFisher, siRNA ID # s72188) was: 5 ’-
CGUGAAAACAUGUACCGCUtt-3’ The scrambled non-target siRNA (silencer select Negative
Control No. 1 siRNA, catalog number 4390844) was purchased from ThermoFisher as well.
For the genome wide human PrPC screen an arrayed silencer select siRNA library purchased
from ThermoFisher was used. The library consisted of 64’752 siRNAs targeting 21’584 tran-
scripts. Each transcript was targeted by three siRNAs. siRNAs targeting the same transcript
were pooled from 186 source plates to 62 low density volume plates (1536-well plates). Three
pooled Prnp-siRNAs and the same scrambled non-target siRNAs were used as controls (from
ThermoFisher, siRNA ID # s11214, s11213, s11212). The siRNA samples were delivered
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in Echo Qualified 384-Well Polypropylene Source Microplates (384PP) that were specifically
used for siRNA printing on the LabCyte Echo acoustic liquid handling platform. siRNA samples
were dispensed using the ”Cherry Pick” software, with sample picking lists and the “Tempo”
scheduling software. siRNA controls were dispensed using the ”Plate Reformat” software and
the ”Tempo” scheduling software.
9.5 Cell seeding and siRNA transfection
For the murine screens CAD5, CAD5 Prnp-/-, HyCAD or scHyCAD cells were harvested when
TPP Tissue Culture (T150) flasks (Sigma) were 70% confluent. A cell suspension with 2800
cells/15 µl Opti-MEM reduced-serum medium (no phenol red, Gibco) plus 10% FBS (HyClone)
was prepared. 15 µl of the cell suspension were dispensed into each well of 384-well tis-
sue culture treated sterile ViewPlate microplates with white well walls and a clear bottom
(Perkin Elmer). For forward transfection siRNAs and Lipofectamine R  RNAiMAX Reagent
(ThermoFisher) in Opti-MEM (Gibco) (final dilution 3x10-3) were added to intermediate plates.
Plates with the transfection mix were centrifuged at 1300rpm for 1min and incubated for 20
minutes at room temperature. 5ul of transfection mix was dispensed into each well with the
Janus robotic platform (Perkin Elmer) using the “Winprep” software. Plates were centrifuged
at 750 rpm x 1 min and incubated at 37 C and 5% CO2. For reverse transfection the plates
with printed siRNAs were frozen at -40 C. At the assay day the plates were thawed and Lipo-
fectamine and 2800 CAD5 cells per well were added and incubated at 37 C and 5% CO2. The
final siRNA concentration was 30nM.
For the human PrPC screen U-251MG cells were harvested when TPP Tissue Culture (T150)
flasks (Sigma) were 70% confluent. A cell suspension with 6000 cells/25 µl Opti-MEM reduced-
serum medium (no phenol red, Gibco) plus 10% FBS (HyClone) was prepared. 25 µl of the
cell suspension were dispensed into each well of white opaque 384-well OptiPlates (Perkin
Elmer). siRNAs from three pooled source plates were printed into eight destination plates.
Control siRNAs were dispensed from a separate plate. The total screen comprised 166 384-
well plates. The plates containing the siRNAs were frozen. At the assay day they were thawed
and Lipofectamine and U-251MG cells were added. The final siRNA concentration was 5nM.
9.6 Cell viability assay
In the murine screens 20 µl of Realtime-Glo (RT-Glo, Promega) in OFBS medium (1: 4000
dilution) were dispensed into each well 24 hrs after transfection. Plates were incubated at 37 C
and 5% CO2 . 48 hours after adding RT-Glo, the plates were taken out from the incubator and
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the RT-Glo luminescence was measured by the Envision Multilabel Reader (Perkin Elmer) at
room temperature and 37 C. In the human screen the cell viability marker RT-Glo was added
after 70 hrs of incubation (1:4 dilution). After 72 hrs the RT-Glo luminescence was measured
with the Envision reader at 37 C. The RT-GloTM cell viability assay is a bioluminescent method,
measuring the reducing potential of cells and thus their metabolism to identify the number of
viable cells in culture. NanoLuc R  luciferase and a cell-permeant pro-substrate are added to
cells in culture. Viable cells reduce the pro-substrate, which leads to the generation of the
substrate for NanoLuc luciferase. This substrate diffuses from the cells into the surrounding
culture medium, where it is cleaved by the NanoLuc enzyme to produce a luminescent signal.
The signal correlates with the number of viable cells.
9.7 PrPC-HP-FRET assay
Immediately after reading the RT-Glo signal, PrPC-HP-FRET was performed. The cell culture
medium was aspirated with the Mircroplate ELx405 Washer (BioTek). Aspiration stopped 1mm
above the well bottom, in order to avoid aspiration of cells. In the murine screen the cells
were subsequently lysed by adding 50 µl/well of 1x standard lysis buffer (50 mM Tris-HCl pH
8, 150 mM NaCl, 0.5% Na deoxycholate, and 0.5% Triton X-100, stored at room temperature).
The plate was shaken at 4 C for 20 min at 700 rpm. The FRET pair comprising the Europium
donor (Eu-W1024 ITC chelate, AD0096, PerkinElmer) and the allophycocyanin acceptor (APC,
AnaTagTM APC labeling kit from AnaSpec) fluorophores, was coupled to POM1 and POM19
anti-PrP antibodies (Polymenidou, Moos et al. 2008). POM1 binds alpha helix 1 of PrP, POM19
recognizes alpha helix 3 of PrP, respectively. The FRET antibody stock Eu-POM19 and APC-
POM1 was diluted with 1x Lance buffer (LANCE R  Detection Buffer for FRET,10x stock, diluted
with dH2O for use) to 25 nM (concentration of POM19 antibody) and 50 nM (concentration of
POM1 antibody). 5 µl/well of 25 nM Eu-POM19 and 5 µl/well of 50nM APC-POM1 were added
separately to the lysed cells. The plates were shaken at 37 C for 1 h at 700 rpm and incubated
over night at 4 C. The plate’s clear bottom was sealed with white BackSeal-384 (Perkin Elmer)
for the top read of time-resolved FRET. In the human screen, 10 µl of 1x standard lysis buffer
were added per well for 2hrs at 4 C after aspiration of the cell culture medium. Europium-POM2
(final conc. 2.5nM) recognizing the octapeptides of PrP and APC-POM1 (final conc. 5nM) were
added and FRET was measured after 4hrs incubation at 4 C. The donor Europium is excited
at wavelength 340 nm and transfers energy to the acceptor APC if the distance between the
FRET antibody pair measures less than 10 nm. APC then emits light at wavelength 665 nm.
The FRET signal of PrPC in each well was detected by the time-resolved EnVision Multilabel
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Reader (Perkin Elmer).
9.8 Preparation of FRET antibody pairs
The monoclonal full-length POM1 as well as POM19 and POM2 antibodies were labelled in
house with Allophycocyanin (APC, AnaTagTM Labeling Kit 72111, Anaspec) and Europium
chelate (Eu-W1024 ITC chelate, AD0096, PerkinElmer) for HP-FRET assays. Europium chelate
served as donor fluorophore. Aromatic isothiocyanate groups of the Europium chelate react
with lysine residues and free N termini of POM19 and POM2 at alkaline pH. To remove com-
pounds that could interfere with labelling (sulfhydryl groups, sodium azide, primary amines),
POM19 and POM2 were diluted in 1ml 100mM sodium carbonate (Na2CO3), pH 9.16, loaded
with a 24G syringe into dialysis cassettes with a cut-off of 10-20 kDa (Slide-A- Lyzer R , Ther-
moFisher), that were pre-incubated in H2O for 2 min, and dialyzed. Dialysis was done under
stirring in 5 L of 100 mM Na2CO3 at 4 C. The dialysis buffer was changed twice after 4-6 h of
incubation and then incubated overnight. POM19 was concentrated by Amicon R  Ultra 2mL
centrifugal filters (Sigma) and the IgG concentration was adjusted upon measuring the protein
concentration with NanoDrop Microvolume Spectrometrer (ThermoFisher) to a concentration
of 5.2 mg/ml. Lyophilized Eu-W1024 ITC chelate (0.1 mg) was stored at - 20 C and imme-
diately before use reconstituted in 20 µl distilled water which resulted in a concentration of 7
mM. A molar excess of 24x of Europium chelate over IgG was added into the POM19 solution
on ice and incubated in 100 mM Na2CO3 overnight at 4 C shaking with 400 rpm. Purification
of the labelled protein from non-reacted chelate was performed by size exclusion chromatog-
raphy (Superdex 200 column, GE Healthcare). Elution from column was done with 50 mM
Tris-HCl pH 7.8 + 0.9% sodium chloride. Sample fractions of 500 µl were collected. The
superdex column was decontaminated with 10 mM phthalate buffer pH 4.1 containing 0.01%
DTPA. Proteins in fractions were separated in a 12% Bis-Tris polyacrylamide gel (NuPAGE;
Invitrogen) and stained with Coomassie blue (BioRad). Fractions with protein were pooled and
concentrated with Amicon R  Ultra 2mL centrifugal filters (Sigma). Labelling ratio and concen-
tration of labelled proteins were assessed by an Eu standard solution (Perkin Elmer) and Nano
drop measurement, respectively. Aliquots of antibodies were stored in liquid nitrogen. Allo-
phycocyanin (APC, AnaTagTM Labeling Kit 72111, Anaspec) was coupled to POM1 antibody
as acceptor fluorophore. Conjugation is established by a covalent bond between maleimide
groups of APC and sulfhydryl groups on POM1. POM1 antibody (1.4 mg/mL) was concen-
trated with Amicon R  Ultra 2mL centrifugal filters (Sigma), that were pre-washed with H2O, in a
Heraeus Multifuge 3SR Plus (DJB labcare) at 4000 x g in swinging buckets for 10 min at 4 C.
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150 µl of POM1 were reduced with 20 µl dithiothreithol (DTT) per mL of IgG solution for 30
min without agitation at RT. Reduced POM1 was desalted on a desalting gravity column (APC,
AnaTagTM Labeling Kit 72111, Anaspec). Fractions of 500 µl were collected and protein con-
centration was measured by NanoDrop Microvolume Spectrometrer (ThermoFisher). Fractions
containing IgG were pooled and again concentrated with with Amicon R  Ultra 2mL centrifugal
filters. 1.33 mg POM1 were conjugated with 2 mg APC at RT for 1h with agitation, protected
from light with aluminium foil. Excess of free thiols was blocked with DMSO and NEM for 30
min at room temperature. Aliquots of antibodies were stored at 4 C and protected from light.
9.9 FRET calculation
The distance-dependent energy transfer between the Eu- and APC-conjugated antibodies in
the presence of PrP results in the FRET signal intensity. The net FRET signal is calculated
from the raw FRET data. Net FRET signals are the number of APC counts depending on FRET
events and calculated by using the following equation (eq.1).
Net FRETsignal = (sample APConly)APC   P · (sample  detection buffer)Eu (1)
The APC background fluorescence and detection buffer are subtracted from the raw FRET
signal of each sample in APC and Eu channels. Spectral overlap compensation is measured
by the proportionality factor P (eq.2)
P =
(Euonly   detection buffer)APC
(Euonly   detection buffer)Eu (2)
APConly and Euonly correspond to all reagents except cells and siRNA in the Eu and APC
channel (Ballmer, Moos et al. 2017).
9.10 PrPSc Enzyme-linked immunosorbent assay (ELISA)
As in the PrPC HP-FRET assay, the cell culture medium was aspirated after reading the RT-Glo
luminescence with the Envision reader at 37 C. Cells were lysed with 50 µl 1x standard lysis
buffer per well, containing 5 µg PK/mL (Roche) to digest PrPC. The assay plate was sealed
and shaken for 90 min at 37 C at 750 rpm. PK was inactivated by adding 8 µl/well of 15 mM
PMSF (stored at -20 C) to reach a final concentration of 1.6 mM. The assay plate was sealed
and shaken for 10 min at room temperature at 750 rpm. To disassemble PK-resistant PrPSc
aggregates to monomers, 7 µl/well of denaturing buffer (sodium hydroxide buffer containing
0.5M NaOH, pH 14.0, stored at RT) were added to reach a final concentration of 47.9 mM.
The assay plate was sealed and shaken for 10 min at RT at 750 rpm. To adjust the pH for
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ELISA, 8 µl/well of neutralizing buffer (phosphate buffer containing 0.5M NaH2PO4, pH 4.0,
stored at RT) were added to get a final concentration of 54.7 mM. The assay plate was sealed
and shaken at RT for 10 min at 750 rpm. 50 µl of the sample solution were transferred to 384-
well Spectraplates HB (Perkin Elmer). The ELISA plates were previously coated with 400 ng/ml
POM1 in PBS at 4 C overnight. Plates were washed five times in PBS + 0.1% Tween-20 (0.1%
PBS-T) and blocked with 80 µl per well of 5% SuperBlock (ThermoFisher) in 0.1% PBS-T for
2 hrs at RT. Blocking buffer was aspirated and samples and controls were added for 90 min at
RT. 2-fold dilutions of rmPrP23-230, starting at a dilution of 1.89 ng/ml in 1x standard lysis buffer
were used as calibration curve. Biotinylated POM19 was used to detect PrPC (200 ng/ml in
1% SuperBlock in 0.1% PBS-T). After washing 5 times with 0.1% PBS-T, biotinylated antibody
was detected by adding 50 µl Streptavidin-HRP (1:1’000 in 1% SuperBlock in 0.1% PBS-T; BD
Pharmingen). Plates were washed again 5 times in 0.1% PBS-T and 50 µl of the chromogenic
HRP substrate 3,3’, 5,5;-tetramethylbenzidine (TMB, Life Technologies) was added to each
well. After ten minutes of incubation at RT, the chromogenic reaction was stopped by adding
50 µl of 0.5 M H2SO4. The absorbance was read at  =450 nm on the EnVision Multilabel
Reader (Perkin Elmer). The blank corresponded to wells filled with all ELISA reagents, but 1x
standard lysis buffer instead of sample solution.
9.11 Screen quality control and data analysis
The raw screening data was analysed by collaborating bioinformaticians (Elke Schaper and
Je´ro`me Dauvellier, Vital-IT lab University of Lausanne and Andra Chincisan, University Hosip-
ital of Zurich) for the quality control reports, data normalization and hit selection.
9.11.1 Quality control
For quality control the strictly standardized mean difference (SSMD) defined for a moderately
strong control was calculated for Net-FRET values of non-target siRNA and Prnp siRNA con-
trols (Zhang 2007). The SSMD is the mean divided by the standard deviation of the difference
between the controls treated with Prnp targeting siRNA and non-target siRNA (eq.3).
SSMD =
meanPrnp  meannon targetq
STDEV P 2rnp2 + STDEV
2
non target
(3)
SSMD levels below -2 indicate that the quality of a screen in the excellent range, for a screen
with a moderate control. SSMD values between -2 and -1 indicate that the screen is in the good
range, whereas SSMD values between -1 and -0.5 indicate the screen is in the inferior range
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(Table 3). For a screen with a strong control SSMD levels below -3 indicate that the quality of
a screen in the excellent range, SSMD values between -3 and -2 indicate that the screen is in
the good range, SSMD values between -2 and -1 indicate the screen is in the inferior range,
whereas SSMD higher than -1 indicate poor screen quality (Zhang 2011).
Quality Type Moderate control Strong control
Excellent SSMD  -2 SSMD  -3
Good -2 < SSMD  -1 -3 < SSMD  -2
Inferior -1 SSMD  -0.5 -2 SSMD  -1
Poor SSMD > -0.5 SSMD > -1
Table 3: SSMD based quality control criteria for moderate and strong controls (Zhang 2011).
The mean value over plates for odd and even rows and columns was compared to check for
row or column effects on the plate. A gaussian fit model chosen by lowest Bayesian information
criterion was applied to the Net-FRET sample values of each plate to process the data and take
in account inter plate variability (Wit, van den Heuvel et al. 2012). Replicate correlation was
calculated by robust linear regression applied to the raw Net-FRET signal of duplicates and
to Gaussian process normalized net-FRET signal. A linear model was fit by robust regression
using an M estimator. Compared to other estimators, M estimators are more robust to outliers,
which is useful for biologically variable screen data from living cells (Wilcox 2012).
9.11.2 Data analysis
Hits were selected based on the best gaussian processed normalized sample signal versus
non-target comparison at a p value threshold = 0.001. For comparison of murine and human
PrPC screens the murine genes were ranked according to the descending Net-FRET signal of
the mean of four siRNAs targeting the same gene. The human genes were ranked according
to the descending mean Net-FRET signal of the technical duplicates targeted by the same
pool of siRNAs against the same gene. The code and the documentation of the customized
High Throughput Screening Library software can be found here: http://elkeschaper.github.io,
https://github.com/elkeschaper/hts
9.12 Brain homogenate preparation used for infection
20% RML6 brain homogenate (BH) was from CD1 mice, infected by intracerebral inoculation
(i.c.) with Rocky Mountain Laboratory strain RML (RML; passage #6) (Mahal, Baker et al.
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2007). 10% 22F BH was from prion strain 22A-infected Hsd;C57BL/6 (BL6) mice, passaged
more than five times. 10% 22L BH was from prion strain 22L-infected Hsd;C57BL/6 (BL6)
mice. 10% 87A BH was from prion strain 87A-infected Hsd;C57BL/6 (BL6) mice. 10% 79A
BH was from prion strain 79A-infected Hsd;C57BL/6 (BL6) mice. 10% ME7 BH was from
prion strain ME7-infected Hsd;C57BL/6 (BL6) mice. 10% mNS BH was from prion strain mNS-
infected JC57BL/6 (BL6) mice. 10% 263K BH was from prion strain 263K-infected Syrian
Hamster PrP transgenic (TgSHaPrP)mice. Non-infectious brain homogenate (NBH) controls
are from the according mice without infection. Brains were removed at the stage of terminal
disease (around 150 days after inoculation), washed two times in 70% Ethanol and four times
in sterile phosphate buffer saline (PBS) and subsequently homogenized in 0.32M sucrose with
the RiboLyser (Hybaid, Catalys). Supernatants were collected in 50 ml Falcon tubes and frozen
at - 40 C.
9.13 Prion infection of cells
Acute infection 1.6 · 105 cells in 2 ml cell culture medium were seeded into 6-well plates
(Corning Costar). After 3 hrs the cells were inoculated with 0.3 µg/mL infectious and non-
infectious brain homogenate (NBH) diluted in 2 ml culture medium and incubated for 96h. After
96 hrs the cells were detached and washed four times with sterile PBS and lysed on ice with
100 µl 1x standard lysis buffer and assayed for PrPSc by PK-Westerns.
Chronical infection 2.5 · 105 cells in 10 ml cell culture medium were seeded into 10cm petri
dishes (Corning Costar). After 3 hrs the cells were inoculated with 0.1 µg/mL infectious and
non-infectious brain homogenate (NBH) diluted in 10 ml culture medium. The medium contain-
ing the inoculum was removed after 4 days and the cells were split 1 : 5 every 3 – 4 days. After
splitting four consecutive slitting steps, the cells were washed two times with sterile PBS, lysed
in 150 µl 1x standard lysis buffer and assayed for PrPSc by PK-Westerns.
9.14 Western blot analysis
Samples containing the same amount of total protein were digested with PK (20 µg protein
per 20 µl, digested with 2 µg or 5 µg PK/ml) in 1x standard lysis buffer for 30 min at 37 C.
PK digestion was stopped by adding 4x loading buffer (NuPAGE; Invitrogen) and boiling the
samples at 95 C for 5 min. Proteins were separated in a 12% Bis-Tris polyacrylamide gel
(NuPAGE; Invitrogen) and blotted onto a nitrocellulose membrane (iBlot R  Transfer Stack, ni-
trocellulose, regular size; Invitrogen). Membranes were blocked with 5% SuperBlock (Ther-
moFisher) in 0.1% PBS-T (Sigma) and incubated with monoclonal mouse POM1 IgG primary
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antibody (anti-PrPC; 200 ng ml–1) in 1% SuperBlock (ThermoFisher). Horseradish peroxidase
(HRP)–conjugated rabbit anti–mouse IgG (1 : 10,000; Zymed) was used as secondary anti-
body. The blots were developed with Luminata Crescendo Western HRP substrate (Sigma)
using the LAS-3000 system (FujiFilm) and the contrast adjusted within the linear range by
Photoshop (Adobe Photoshop CS6) (Zhu, Herrmann et al. 2016).
9.15 Immunoprecipitation
9.15.1 Preparation of dynabeads
Dynabeads Protein A for Immunoprecipitation (Invitrogen) were resuspended by vortexing. The
supernatant was removed, while the tubes were on a magnetic rack. The dynabeads were
washed twice with coating buffer (0.1% BSA albumin in PBS; essentially globulin-free, Sigma).
Beats treated with and without POM1 IgG anti-PrPC antibody (1.5 µg per 25 ul dynabeads)
were incubated 2h at RT on a rotating wheel. Then the beads were washed three times with
coating buffer.
9.15.2 Preparations of samples and IP
SH-SY5Y and HEK293 wt and PRNP-/- cells of both cell lines were lysed in Co-IP buffer
(50 mM Tris-Cl, 1% Igepal (NP-40), 75 mM NaCl, pH 7.4) plus CompleteTM Mini Protease
Inhibitor Cocktail (Roche). 2000 µg of protein were diluted in 1 ml of ice cold Co-IP buffer plus
CompleteTM Mini Protease Inhibitor Cocktail (Roche), passed five times through a syringe
and incubated for 30 min on a rotating wheel at 4 C. After centrifuging at 900 x g for 3 min, the
supernatant was collected and transferred to new tubes. For pre-clearing, the samples were
incubated dynabeads that had not been treated with POM1, resuspended in 0.5% BSA (Sigma)
in PBS for one hour at room temperature on a rotating wheel. The supernatant was transferred
to new tubes, dynabeads + POM1 or Mouse IgG isotype control (Abcam) were added and
immunoprecipitation was carried out over night at 4 C. The supernatant was removed and the
samples were washed twice in washing buffer (50 mM Tris-Cl, 0.5% Igepal, 150 mM NaCl,
pH 7.4) and proteins eluted with 2x loading buffer (NuPAGE; Invitrogen) by boiling for 5 min at
95 C. Samples were immediately put on the magnetic rack for 12 min and the supernatant was
used for western. The western was performed as described above with biotinylated POM2 IgG
primary antibody (anti-PrPC; 200 ng/ml) in 1% SuperBlock (ThermoFisher) and Avidin-HRP
(1:000; BD-Pharmacon) in 1% SuperBlock (ThermoFisher).
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9.16 Gradient centrifugation
900 µl of 10%, 20%, 30%, 40%, 50%, and 60% sucrose solutions were prepared and layered
with decreasing concentration into 5pA tubes (ThermoFisher) suitable for the SS-52ST rotor
of Sorvall Discovery M150 Micro-Ultracentrifuge (VBI Core Labs). Samples were diluted in
1x standard lysis buffer to a final concentration of 0.6 µg/µl and rotated for 20 min at 4 C on
the rotation wheel to solubilize PrPC. Then, the samples were centrifuged for 5 min at 4 C at
15’000 rpm to pellet down cell debris. 500 µl of the supernatant was added on top of the su-
crose gradient. The samples were centrifuged for 1 hour at 4 C at 50’000 rpm with the Sorvall
Discovery M150 Micro-Ultracentrifuge (VBI Core Labs). Fractions a 400 µl were collected into
fresh 2ml screw cap tubes and precipitated with 1.8 ml MeOH at - 40 C, overnight. Samples
were then centrifuged for 30 min at 4 C at 13’000 rpm. The MeOH was removed and samples
completely dried by evaporation in the hood. Samples were re-suspended with 30 µl 2x load-
ing buffer (NuPAGE; Invitrogen) and samples were boiled for 5 min at 95 C. The western was
performed as described above.
9.17 POM1- POM2 Sandwich ELISA
ELISA with PRNP-/- candidate protein samples was performed in SpectraPlate-96 MB, Clear
96-well Microplate with Medium Protein Binding Affinity (Perkin Elmer) as described above,
but with biotinylated POM2 antibody, instead of POM19. Unknown PrPC concentrations were
interpolated from the linear range of the calibration curve with rhPrP22-231. Each sample was
compared with unpaired two tailed t test to the positive control.
9.18 Immunohistochemistry of cell monolayers
700 µl cells (750’000 cells/ml) were seeded into glass bottom µ-slide chamber slides (Ibidi)
and incubated for 48 hrs. For staining of intracellular PrP the cells were washed two times with
sterile PBS and fixed and permeabilized with ice-cold acetone for 5 min. Cells were washed
again two times and blocked for one hour at room temperature with 10% goat serum (DAKO)
and 5% bovine serum albumin (BSA) in PBS. Samples were incubated for one hour at room
temperature with monoclonal mouse POM1 IgG primary antibody (anti-PrPC; 1 µg /ml) in 1%
SuperBlock (ThermoFisher). Alexa 488 conjugated goat anti–mouse IgG (1:1000; Sigma) in
1% SuperBlock (ThermoFisher) was used as secondary antibody and incubated for one hour
at room temperature. After washing three times the nuclei were stained with DAPI (1:10’000;
Sigma) in PBS for 5 min and samples washed again tree times with sterile PBS before being
131
imaged on a SP5 confocal microscope (Leica) using a 63 x oil immersed HCX PL APO Leica
objective (NA 1.4, WD 0.1mm) at 3 x optical zoom. Laser intensities were kept constant across
treatment groups during imaging.
9.19 Cell growth assessment
Quantification of the cell growth was assessed with the IncuCyte ZOOM live-cell analysis sys-
tem (Essenbioscience). Cells were seeded into 384-well plates. Brightfield images were taken
every 12 hrs. Data was analysed and visualized with the IncuCyte ZOOM Software using a
confluency mask.
9.20 Real-time quantitative PCR
CAD5 cells transfected with different siRNAs were cultured in 6-well plates and harvested after
72 hrs at 70% confluency. RNA was extracted with the RNeasy Mini kit (QIAGEN). cDNA was
generated according to the QuantiTect Reverse Transcription kit (QIAGEN) by eliminating ge-
nomic DNA in a first step followed by reverse transcription. All reactions were set up on ice to
minimize the risk of RNA degradation. Primers for real-time quantitative PCR (qRT-PCR) were
designed using the primer bank from Harvard: https://pga.mgh.harvard.edu/primerbank/index.html.
To check the linear range of the qRT-PCR primers, each primer pair was tested with a stan-
dard curve consisting of five 1:10 dilutions of CAD5 wild type (wt) RNA starting at 100 ng
RNA. Absolute mRNA expression was assessed by qRT-PCR. Technical triplicates of three
biological replicates from different passages of CAD5 wt cells transfected with siRNAs target-
ing chaperones, Prnp and scrambled non-target siRNA were used. cDNA generated without
reverse transcriptase and H2O served as negative controls. The qPCR was performed in 96-
and 384-well plates. The PCR reaction mix consisted of forward and reverse primer [final
conc. 250nM], 1x SYBR green (Roche Diagnostics) and H2O. The final cDNA concentration
was 0.5ng/mL. The reagents were dispensed manually and by a LabCyte acoustic dispensing
robot. The reaction was run on a ViiA7 Real-Time PCR System (Life Technologies). Eight
different housekeeping genes (B2m, Eif2a, Gapd, Hmbs, Hprt, Ppib, Tbp, Utp6c) were tested.
B2m, Gapdh, Hprt and Ppib were selected as reliable ones and used in every experiment as
controls. All samples were normalized to Hprt. Absolute mRNA levels were calculated with the
ViiA7 software, Microsoft Excel and GraphPad software.
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9.21 Proteomics
The proteomic composition of the neuronal CAD5 cells was characterized by Pierre Goloubinoff
and Bruno Fauvet. Herein 4142 proteins, representing 96.8% of the total mass of polypeptides,
were quantified significantly above the back-ground noise (n=5 biological repeats; unpaired
t-test using an initial p-value threshold of 0.01), out of 8403 protein identifications. The quanti-
tative values as mass fractions and copy number per cubic micron were implemented into the
chaperone hit characterization.
9.22 Statistical analysis
Statistical tests were computed by GraphPad Prism 5 (GraphPad) and Excel (Version 16.13.1).
GraphPad Prism 5 and R Markdown were used for data visualization. Statistical significance
between experimental groups was assessed using an unpaired t-test or two-way analysis of
variance (ANOVA). p-values <0.05 were considered statistically significant. Results were pre-
sented as the mean of replicas ± SD unless stated otherwise.
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10 Appendix
Figure 79: The randomized screen plate layout showed 192 samples (yellow), CAD5 Prnp-/- cells in the first
two columns cells (blue). The control wells with non-target siRNA (purple) and with Prnp targeting siRNA (red)
were evenly distributed over the plate. The last two columns contained the buffer controls with LANCE buffer
(grey), Europium coupled to POM19 (dark blue), APC coupled to POM1 (orange) and a mixture of both detection
antibodies (pink).
Figure 80: Cell viability quality control of the first PrPC screen. In the first murine PrPC screen each gene was
targeted by two up to four different siRNAs in technical duplicates. Gene names were coloured according to the
number of siRNAs targeting the same gene that led to modulation of PrP levels. Genes were targeted by four
(yellow), three (dark orange) two siRNAs (bright orange) or one siRNA (blue). Each siRNA was assessed for cell
viability and marked with blue if it passed the quality control and orange if it did no pass. The viability range was
defined by the mean of non-target controls +/- 2 SD. Genes that were targeted by less than 4 siRNAs showed
missing values in grey.
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Figure 80: (Description on the previous page)
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Figure 81: Cell viability quality control of the second PrPC screen. In the second murine PrPC screen each gene
was targeted by four different siRNAs in technical duplicates. Gene names were coloured according to the number
of siRNAs targeting the same gene that led to modulation of PrP levels. Genes were targeted by one (blue) or two
siRNAs (bright orange). Each siRNA was assessed for cell viability and marked with blue if it passed the quality
control and orange if it did no pass. The viability range was defined by the mean of non-target controls +/- 2 SD.
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Figure 82: Summary of all chaperone hits from the first and second PrPC screen. Gene names were coloured
according to the number of siRNAs targeting the same gene that led to modulation of PrP levels. Genes were
targeted by four (yellow), three (dark orange) or two siRNAs (bright orange). The number of siRNAs in duplicates,
that passed (TRUE) or failed (FALSE) RT-Glo quality control were indicated in a column. The functions of each
gene were indicated in the last column uniprot.org.
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Figure 82: (Description on the previous page)
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Figure 83: Summary of all chaperone hits from the first and second PrPC screen. Gene names were coloured
according to their function. ER associated function (yellow), Proteasome (grey), Apoptosis (blue) and genes that
led to upregulation of PrP were coloured in green.
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Figure 84: Summary of the function of the genes that reduced cell viability in the PrPSc screen.
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Figure 85: List of the housekeeping genes, their functions and according primers used for the qRT-PCR for hit
validation.
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